eyes-10q_20200331.htm

0001564590-20-030851.txt : 20200626 0001564590-20-030851.hdr.sgml : 20200626 20200626165634 ACCESSION NUMBER: 0001564590-20-030851 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200626 DATE AS OF CHANGE: 20200626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0001266806 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36747 FILM NUMBER: 20994780 BUSINESS ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 BUSINESS PHONE: 818-833-5000 MAIL ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 10-Q 1 eyes-10q_20200331.htm 10-Q eyes-10q_20200331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number 001-36747

Second Sight Medical Products, Inc.

(Exact name of Registrant as specified in its charter)

California

02-0692322

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

12744 San Fernando Road, Suite 400, Sylmar, CA 91342

(Address of principal executive offices, including zip code)

(818) 833-5000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock

EYES

NASDAQ

Warrants

EYESW

NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

As of June 25, 2020, the registrant had 23,118,233 shares of common stock, no par value per share and 7,682,244 warrants, outstanding.

EXPLANATORY NOTE

As previously disclosed in the Current Report on Form 8-K filed by Second Sight Medical Products, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 12, 2020, the filing of this Quarterly Report on Form 10-Q for the period ended March 31, 2020 (this “Form 10-Q”) was delayed due to circumstances related to the ongoing COVID-19 global pandemic. In compliance with local governmental “shelter in place” measures and to limit the risk of exposure to and transmission of the SARS-CoV-2 virus, which causes COVID-19, access to the Company’s facilities has been restricted and the Company’s employees have a minimal presence in its offices for essential activities. These restrictions caused limited access to the Company’s facilities and disrupted normal interactions among the Company’s accounting personnel and other staff, all of which slowed the completion of the Company’s quarterly review and preparation of the Form 10-Q. Accordingly, the Company’s ability to complete its quarterly review and to prepare and file the Form 10-Q by the original SEC filing deadline had been hampered. As a result, the Company relied on the “Order under Section 36 of the Securities Exchange Act of 1934 Modifying Exemptions From the Reporting and Proxy Delivery Requirements for Public Companies” dated March 25, 2020 (Release No. 34-88465) issued by the SEC to delay the filing of this Form 10-Q.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

FORM 10-Q

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of March 31, 2020 (unaudited) and December 31, 2019	4
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (unaudited)	5
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2020 and 2019 (unaudited)	6
	Condensed Consolidated Statements of Stockholders’ Equity (Deficiency) for each of the three-month periods ended March 31, 2020 and 2019 (unaudited)	7
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	27

PART II	OTHER INFORMATION

Item 1.	Legal Proceedings	28

Item 1A.	Risk Factors	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32

Item 3.	Defaults Upon Senior Securities	32

Item 4.	Mine Safety Disclosures	32

Item 5.	Other Information	32

Item 6.	Exhibits	33

SIGNATURES		34

Part I. Financial Statements

Item 1. Financial Statements

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Balance Sheets

(in thousands)

	March 31,			December 31,
	2020			2019
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	2,339		$	11,327
Accounts receivable, net		—			455
Inventories, net		—			1,029
Assets held-for-sale		400			—
Prepaid expenses and other current assets		926			299
Total current assets		3,665			13,110
Property and equipment, net		232			1,122
Right-of-use assets		—			2,342
Deposits and other assets		7			25
Total assets	$	3,904		$	16,599
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Current liabilities:
Accounts payable	$	1,588		$	1,093
Accrued expenses		1,575			1,889
Accrued compensation expense		885			2,698
Accrued clinical trial expenses		733			707
Current operating lease liabilities		106			237
Contract liabilities		335			335
Total current liabilities		5,222			6,959
Long term operating lease liabilities		—			2,365
Total liabilities		5,222			9,324
Commitments and contingencies
Stockholders’ equity (deficiency):
Preferred stock, no par value, 10,000 shares authorized; none outstanding		—			—
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,657 and 15,643 as of March 31, 2020 and December 31, 2019, respectively		264,003			264,008
Additional paid-in capital		48,892			48,613
Accumulated other comprehensive loss		(543	)		(562	)
Accumulated deficit		(313,670	)		(304,784	)
Total stockholders’ equity (deficiency)		(1,318	)		7,275
Total liabilities and stockholders’ equity (deficiency)	$	3,904		$	16,599

See accompanying notes.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except per share data)

	Three Months Ended March 31,
	2020			2019
Net sales	$	—		$	1,128
Cost of sales		—			731
Gross profit		—			397

Operating expenses:
Research and development, net of grants		3,887			2,183
Clinical and regulatory, net of grants		914			1,006
Selling and marketing		701			2,103
General and administrative		2,021			2,449
Restructuring charges		1,381			2,424
Total operating expenses		8,904			10,165

Loss from operations		(8,904	)		(9,768	)
Interest income		18			68

Net loss	$	(8,886	)	$	(9,700	)

Net loss per common share – basic and diluted	$	(0.57	)	$	(0.80	)

Weighted average common shares outstanding – basic and diluted		15,649			12,071

See accompanying notes.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Comprehensive Loss (unaudited)

(in thousands)

	Three Months Ended March 31,
	2020			2019
Net loss	$	(8,886	)	$	(9,700	)

Other comprehensive income (loss):
Foreign currency translation adjustments		19			(8	)
Comprehensive loss	$	(8,867	)	$	(9,708	)

See accompanying notes.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Stockholders’ Equity (Deficiency) (unaudited)

(in thousands)

		Common Stock							Additional Paid-in		Accumulated Other Comprehensive		Accumulated						Total Stockholders’
		Shares		Amount					Capital		Loss		Deficit						Equity
Balance, December 31, 2018	9,542				$	229,019		$	44,111	$	(575	)			$	(269,471	)	$	3,084
Adoption of ASC Topic 842-Leases	—					—			—		—					(144	)		(144	)
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs	5,976					34,399			—		—					—			34,399
Release of restricted stock units	7					—			—		—					—			—
Warrants modification (see note 7)	—					—			1,577		—					(1,577	)		—
Stock-based compensation expense	—					—			898		—					—			898
Net loss	—					—			—		—					(9,700	)	(9,700)
Foreign currency translation adjustment	—					—			—		(8	)				—			(8	)
Balance, March 31, 2019	15,525				$	263,418		$	46,586	$	(583	)			$	(280,892	)	$	28,529

		Common Stock							Additional Paid-in		Accumulated Other Comprehensive		Accumulated						Total Stockholders’
		Shares				Amount			Capital		Loss		Deficit						Equity(Deficiency)
Balance, December 31, 2019	15,643				$	264,008		$	48,613	$	(562	)		$		(304,784	)	$	7,275
Repurchase of fractional shares in connection with reverse stock split	(2		)			(11	)		—		—					—			(11	)
Issuance of shares of common stock	1					6			—		—					—			6
Release of restricted stock units	15					—			—		—					—			—
Stock-based compensation expense	—					—			279		—					—			279
Net loss	—					—			—		—					(8,886	)	(8,886		)
Foreign currency translation adjustment	—					—			—		19					—			19
Balance, March 31, 2020	15,657				$	264,003		$	48,892	$	(543	)		$		(313,670	)	$	(1,318	)

See accompanying notes.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended March 31,
	2020			2019
	(unaudited)
Cash flows from operating activities:
Net loss	$	(8,886	)	$	(9,700	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		106			99
Stock-based compensation		279			898
Non-cash lease expense		3			6
Restructuring charges-inventory and fixed asset impairment		1,115			2,424
Changes in operating assets and liabilities:
Accounts receivable		455			(95	)
Inventories		(112	)		(786	)
Prepaid expenses and other assets		(610	)		236
Accounts payable		497			297
Accrued expenses		286			(57	)
Accrued compensation expenses		(1,813	)		(609	)
Accrued clinical trial expenses		26			84
Contract liabilities		—			53
Net cash used in operating activities		(8,654	)		(7,150	)
Cash flows from investing activities:
Purchases of property and equipment		(331	)		(37	)
Net cash used in investing activities		(331	)		(37	)
Cash flows from financing activities:
Net proceeds from sale of common stock and/or warrants		6			34,399
Repurchase of fractional shares in connection with reverse stock split		(11	)		—
Net cash (used in) provided by financing activities		(5	)		34,399
Effect of exchange rate changes on cash and cash equivalents		2			(1	)
Cash and cash equivalents:
Net increase (decrease)		(8,988	)		27,211
Balance at beginning of period		11,327			4,471
Balance at end of period	$	2,339		$	31,682

See accompanying notes.

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Organization and Business Operations

Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in 2003. Second Sight develops implantable visual prosthetics to potentially enable blind individuals to achieve greater independence.

In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials and sales and marketing in Europe, the Middle East and Asia-Pacific, and more recently for the research of future technologies. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of March 31, 2020. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

We are currently developing the Orion^® Visual Cortical Prosthesis System (“Orion”), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes including retinitis pigmentosa (RP), glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The FDA granted Breakthrough Devices Program designation for Orion. A feasibility study of the Orion device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and Baylor College of Medicine in Houston (“Baylor”).

Our first product that was commercially approved, the Argus^® II retinal prosthesis system (“Argus II”), entered clinical trials in 2006, received CE Mark approval for marketing and sales in the European Union (“EU”) in 2011, and received approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in 2013. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Given the limited addressable market of Argus II, we no longer market the Argus II and have focused all of our resources on the development of Orion.

In March 2020, we were severely adversely impacted by the COVID-19 pandemic and its related effects on our ability to finance our planned activities. As a result, we significantly reduced our staff and expenses and conserved liquidity as we continue operations and explore strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not be in a related industry. No assurances can be given that any of these initiatives will occur.

Liquidity and Going Concern

From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2017 has been primarily provided by:

•

Issuance of shares of common stock on May 5, 2020 which provided net proceeds of approximately $6.6 million.

•

Issuance of common stock and warrants in a Rights Offering in February 2019 which provided $34.4 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2019 which provided $0.1 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the first quarter of 2018, which provided $4.0 million of net cash proceeds

•

Issuances of common stock via stock purchase agreements in May, August, October and December 2018, which provided net cash proceeds of $22.0 million

•

Revenue of $3.4 million and $6.9 million, for the years ended December 31, 2019 and 2018, respectively, generated by sales of our Argus II product

On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.6 million.

We received an award for $1.6 million grant (with the intent to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018. Our second year grant was recently approved under this grant. As of March 31, 2020 we recorded $0.3 million of deferred grant costs, included in prepaid expenses and other current assets, associated with this grant which were offset with the related grant funds when received in April 2020.

On September 17, 2019, we received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (“SLAM”). This grant involves a joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), and is intended to speed the integration of SLAM into future generations of Orion. The goal is to give Orion users the ability to localize objects and navigate landmarks in unfamiliar surroundings in real time. APL is the primary recipient of the grant. We have suspended our activities on the project until we clarify our future plans.

In a rights offering completed on February 22, 2019, we sold approximately 5,976,000 million units, each priced at $5.792 for net proceeds of approximately $34.4 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $11.76 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 5,180,000 million units in the offering for an aggregate investment of approximately $30 million.

In November 2017, we entered into an At Market Issuance Sales Agreement (“Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we offered and sold, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold approximately 278,000 shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement. During December 2019, we sold approximately 17,000 shares of common stock which provided net proceeds of $0.1 million under the Sales Agreement. In April 2020, we terminated the Sales Agreement with the Agents.

Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing a novel medical device, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.

As more fully described in Note 11, we have been notified by the Nasdaq stock market regarding our non-compliance with the continued listing requirement on the Nasdaq capital market pursuant to its listing rules, and therefore we could be subject to delisting if we do not regain compliance within the compliance period (or the compliance period as may be extended).

Based upon our current plans we do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. Accordingly, these and other related factors raise substantial doubt about our ability to continue as a going concern. We anticipate that we will seek to additionally fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or any other approved product candidates, or we may be unable to maintain our current limited operations, maintain our current organization and reduced employee base or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Reverse Stok Split

On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020.

The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.

Significant Accounting Policies

Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.

Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.4 million related to inventory of Argus II in the three months ended March 31, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million. In addition, we recorded an impairment of $0.7 million to our fixed assets used primarily for Argus activities and $0.2 million in severance payments all of which were paid in May 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations.

Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.

Recently Issued Accounting Pronouncements

We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

3. Concentration of Risk

Credit Risk

Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extended differing levels of credit to our customers, and typically did not require collateral.

Customer Concentration

The following tables provide information about disaggregated revenue by service type, customer and geographical market.

The following table shows our revenues by customer type during the three months ended March 31, 2020 and 2019:

	Three Months Ended March 31,
	2020		2019
Direct customers	$	—	$	946
Indirect customers (distributors)		—		182
Total	$	—	$	1,128

During the three months ended March 31, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues:

	Three Months Ended March 31,
	2020			2019
Customer 1		—	%		23	%
Customer 2		—	%		15	%
Customer 3		—	%		13	%
Customer 4		—	%		12	%
Customer 5		—	%		12	%
Customer 6		—	%		10	%
Customer 7		—	%		10	%

As of March 31, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable:

	March 31, 2020			December 31, 2019
Customer 1		—	%		35	%
Customer 2		—	%		33	%
Customer 3		—	%		32	%

Geographic Concentration

During the three months ended March 31, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:

	Three Months Ended March 31,
	2020			2019
United States		—	%		60	%
Italy		—	%		23	%
Korea		—	%		10	%

Foreign Operations

The accompanying condensed consolidated financial statements as of March 31, 2020 and December 31, 2019 include gross assets amounting to $1.0 million and $1.3 million, respectively, relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.

4. Fair Value Measurements

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

Cash equivalents, which includes money market funds, are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs.

Assets measured at fair value on a recurring basis are as follows (in thousands):

	Total		Level 1		Level 2		Level 3
March 31, 2020 (unaudited):
Money market funds	$	2,179	$	2,179	$	—	$	—
December 31, 2019:
Money market funds	$	11,307	$	11,307	$	—	$	—

5. Selected Balance Sheet Detail

Inventories, net

Inventories consisted of the following (in thousands):

	March 31,			December 31,
	2020			2019
Raw materials	$	823		$	803
Work in process		1,699			1,716
Finished goods		1,282			2,069
		3,804			4,588
Allowance for excess and obsolete inventory and impairment charge		(3,804	)		(3,559	)
Inventories, net	$	—		$	1,029

We recorded $2.4 million as an impairment charge during the three months ended March 31, 2019, related to our plans to suspend Argus II production. We recorded further impairment charges to our inventory of $0.5 million in the first quarter of 2020. Additionally, finished goods inventory amounting to approximately $0.75 million that we expect to use for our future warranty claims has been offset with the warranty accrual which is included in accrued expenses.

Property and equipment

Property and equipment consisted of the following (in thousands):

	March 31,			December 31,
	2020			2019
Laboratory equipment	$	584		$	2,724
Computer hardware and software		69			1,672
Leasehold improvements		—			304
Furniture, fixtures and equipment		—			78
		653			4,778
Accumulated depreciation and amortization		(421	)		(3,656	)
Property and equipment, net	$	232		$	1,122

As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million related to our fixed assets used primarily for Argus activities. We have additionally reclassified $0.4 million as assets held-for-sale which represents the estimated fair value of fixed assets that we plan to sell through auction.

Contract Liabilities

Contract liabilities consisted of the following (in thousands):

Beginning balance as of December 31, 2019	$	335
Consideration received in advance of revenue recognition		—
Revenue recognized		—
Ending balance as of March 31, 2020	$	335

Product Warranties

A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2020 is presented below:

Beginning balance as of December 31, 2019	$	1,575
Additions		—
Settlements		(60)
Adjustments and other		—
Total		1,515
Less: Finished goods inventory expected to be used for future warranty claims		(750)
Ending balance as of March 31, 2020	$	765

Allowance for Doubtful Accounts

Allowance for doubtful accounts consisted of the following (in thousands):


Beginning balance as of December 31, 2019	$	117
Additions		—
Write-offs		(117)
Ending balance as of March 31, 2020	$	—

Right-of-use assets and operating lease liabilities

We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments.

On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date not later than June 18, 2020 (“Accelerated Termination Date”). We agreed to pay the Landlord (i) $210,730 to bring the Leases current (the “Owed Rent”) and to remit (ii) a one-time early termination fee in the amount of $150,000 (the “Early Termination Amount”). Prior to the early termination agreed in this letter we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the term remaining under the Leases through the respective expiration dates in February 2022 and April 2023. The Landlord acknowledged that as of the date of the Letter Agreement the Owed Rent and the Early Termination Amount constituted all amounts owing to the Landlord under the Leases. As a result of the letter agreement, we wrote down the right-of-use assets and extinguished related lease liabilities in the amounts of $2.3 million and $2.4 million, respectively. We have accrued an early termination fee of $150,000 which is included in accrued expenses and restructuring charges as of and for the three months ended March 31, 2020.

Assets	Classification	March 31, 2020		December 31, 2019
Non-current assets	Right-of-use assets	$	—	$	2,342
Liabilities
Current	Current operating lease liabilities	$	106	$	237
Long term	Long term operating lease liabilities	$	—	$	2,365

The components of lease expense for the three months ended March 31, 2020 and 2019 were as follows (unaudited):


	For the three months ended March 31, 2020		For the three months ended March 31, 2019
Lease expense:
Operating lease expense	$	123	$	123
Short-term lease expense		—		—
Total lease expense	$	123	$	123

Cash paid for lease amounts included in the measurement of lease liabilities amounted to $121,000 and $117,000, respectively, during the three months ended March 31, 2020 and 2019.

6. Equity Securities

Increase in Authorized Shares of Common Stock

On June 4, 2019, our shareholders approved an amendment to our restated articles of incorporation increasing our authorized no par value shares of common stock from 200 million to 300 million shares.

Potentially Dilutive Common Stock Equivalents

As of March 31, 2020 and 2019, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).

	March 31,
	2020		2019
Common stock warrants issued to underwriter of initial public offering		—		100
Common stock warrants issued in connection with March 2017 rights offering		1,706		1,706
Common stock warrants issued in connection with February 2019 rights offering		5,976		5,976
Common stock options		890		1,073
Restricted stock units		25		64
Employee stock purchase plan		—		56
		8,597		8,975

7. Warrants

On February 22, 2019, we completed a registered rights offering to existing stockholders in which we sold approximately 5,976,000 units at $5.792 per unit, which was the adjusted closing price of our common stock on that date. Each Unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants had a five-year life and trade on Nasdaq under the symbol EYESW.

On March 6, 2017, we completed a registered rights offering to existing stockholders in which we sold approximately 1,706,000 units at $11.76 per unit, which was the adjusted closing price of our common stock on that date. Each unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants have a five-year life and have been approved for trading on Nasdaq under the symbol EYESW. As of March 31, 2020, 632 of the warrants associated with the rights offering had been exercised.

We extended the term of 1.7 million warrants issued in our March 2017 rights offering by approximately two years effective as of February 15, 2019 as part of our February 2019 rights offering. We determined the fair value of the March 2017 Warrants immediately before and after the modification. The fair value of the March 2017 Warrants after the modification was increased by approximately $1.6 million, resulting in an accounting adjustment to additional paid-in capital and accumulated deficit in the consolidated statements of shareholders’ equity. The assumptions used in the determination of fair value of the warrants before and after the extension included a risk free interest rate of 2.50% and 2.49%, expected volatility of 81% and 82%, and expected lives of 3.08 years and 5.08 years, respectively and 0% dividend yields for both.

A summary of warrants activity for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).

	Number of Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in Years)
Warrants outstanding as of December 31, 2019		7,682	$	11.76		4.21
Issued		—
Exercised		—
Forfeited or expired		—
Warrants outstanding as of March 31, 2020		7,682	$	11.76		3.96
Warrants exercisable as of March 31, 2020		7,682	$	11.76		3.96

The warrants outstanding as of March 31, 2020 had no intrinsic value.

8. Stock-Based Compensation

A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).

	Number of Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in Years)
Options outstanding as of December 31, 2019		984		$	21.78		7.70
Granted		206		$	5.98
Exercised		—		$
Forfeited or expired		(300	)	$	12.45
Options outstanding as of March 31, 2020		890		$	21.27		3.12
Options exercisable as of March 31, 2020		517		$	30.34		2.01

The estimated aggregate intrinsic value of stock options exercisable as of March 31, 2020 was zero. As of March 31, 2020, there was $1.8 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.59 years.

During the three months ended March 31, 2020, we granted stock options to purchase 205,701 shares of common stock to certain employees. The options are exercisable for a period of ten years from the date of grant at $5.98 per share, which was the fair value of our common stock on the respective grant date. The options generally vest over a period of four years . The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be $0.8 million ($4.05 per share) using the following assumptions: expected term of 6.02 years, volatility of 78.0%, risk-free interest rate of 1.50% and expected dividend rate of 0.0%. During the quarter ended March 31, 2020 approximately 300,000 options were canceled and expired resulting in a reduction of stock option expense for the period of approximately $167,000.

The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2020 (in thousands, except per share data):

	Number of Shares			Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2019		61		$	5.92
Awarded		—			—
Vested and released		(15	)		5.92
Forfeited/canceled		(21	)		5.92
Outstanding as of March 31, 2019		25		$	5.92

As of March 31, 2020, there was $0.1 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.89 years.

We adopted an employee stock purchase plan in June 2015 for all eligible employees. At March 31, 2020 the available number of shares that may be issued under the plan is 77,031.

Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 was as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cost of sales	$	—	$	47
Research and development		102		187
Clinical and regulatory		15		34
Selling and marketing		41		130
General and administrative		121		500
Total	$	279	$	898

9. Risk and Uncertainties

In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread globally. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, most states in the U.S., including California, where we are headquartered, have declared a state of emergency. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns.

In accordance with local and state guidelines regarding the COVID-19 pandemic, we are requiring all of our employees to work remotely unless they cannot perform their essential functions remotely, and have also suspended all non-essential travel for our employees. While a significant number of our employees may be accustomed to working remotely or working with other remote employees, much of our workforce has not historically been remote. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance becomes available, temporarily suspending travel and restricting the ability to do business in person may create operational or other challenges, any of which could harm our business, financial condition and results of operations.

In addition, our clinical trials may be affected by the COVID-19 outbreak. Patient visits in ongoing clinical trials may be delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. For example, scheduled patient visits to our clinical sites at UCLA and Baylor were temporarily put on hold due to COVID-19 and we are in the process of planning to resume patient visits with the sites. In addition, the validation study for the revised FLORA assessment was paused due to travel requirements for its completion. Also, some of our suppliers of certain materials used in the development of our product candidates are located in areas impacted by COVID-19 which could limit our ability to obtain sufficient materials for our product candidates. COVID-19 has and will continue to adversely affect global economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our product candidates, if approved, and impact our operating results. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of the continued global economic impact of the pandemic. We could experience further harm to our business and we cannot anticipate all of the ways in which health epidemics such as COVID-19 could adversely impact our business. Although we are continuing to monitor and assess the effects of the COVID-19 pandemic on our business, the ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change.

COVID-19 has directly and indirectly adversely affected Second Sight and will likely continue to do so for an uncertain period of time. In March and April 2020 we laid off a substantial majority of our employees as a result of COVID-19 and an inability to obtain financing. We retain approximately 10 of our employees to oversee current operations. The cumulative effects of COVID-19 on the Company cannot be predicted at this time, but could include, without limitation:

•

inability to meet warranty obligations for our Argus II products;

•

reputational damages of the Company and its products;

•

inability to raise additional funds to finance and continue our operations;

•

inability to maintain adequate office laboratory facilities;

•

inability to retain and hire experienced personnel;

•

inability to finalize our plan for and enroll patients into our proposed pivotal clinical trial;

•

material delays or inability to complete development and commercialization of Orion;

•

inability to satisfy Nasdaq’s continued listing requirements and possible delisting; and

•

other uncertain events that may have negative impact effect on our operations.

10. Litigation, Claims and Assessments

Ten oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. We have filed one opposition that is currently pending in the European Patent Office challenging the validity of a patent owned by Pixium Vision. The outcome of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations.

By letter received June 23, 2020 counsel for a participant in the Orion Early Feasibility Study has alleged claims against the Company for breach of contract, breach of the implied covenant of good faith and fair dealing, negligent misrepresentation, promissory estoppel and negligent infliction of emotional distress. Counsel in addition has alleged that Second Sight has violated the protocol established by the FDA for good clinical practice within this industry. As full compensation for damages arising from these claims the Company was presented with a demand for payment of $3,000,000. The Company believes that the claims asserted are without merit. The Company will seek to deter the filing of this claim. However, these claims are in the early stage and no assurance can be given that this matter will not result in litigation. To the extent a lawsuit is filed, the Company intends to vigorously defend it.

We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors

11. Subsequent Events

Work Force Reductions

After our work force reduction on March 31, 2020 we initiated a further reduction on April 17, 2020 to our current employment status of 10 employees. The costs for this reduction have been recorded in the quarter ended June 30, 2020.

Employment Agreements

On May 13, 2020 we entered into an agreement with John T. Blake, our Chief Financial Officer, for an amendment to Mr. Blake’s Executive Employment Agreement dated March 21, 2018 pursuant to which we agreed to pay Mr. Blake a one-time cash bonus of $100,000 (the “Bonus”) in recognition of his services. Under the Amendment, Mr. Blake will be entitled to receive all separation amounts due to him pursuant to the Employment Agreement less the amount of Bonus in the event that his employment is terminated without cause.

On May 8, 2020, our board of directors approved payment to Patrick Ryan, our former Chief Operating Officer, of approximately $471,000 and to reimburse up to 12 months of COBRA, if elected, pursuant to the terms of Mr. Ryan’s employment agreement. Mr. Ryan was separated effective April 17, 2020.

Subsidiary Closure

In May 2020, we initiated the process to investigate the closure of our Swiss subsidiary due to our decision to cease marketing the Argus II product and to reduce operating expenses.

Nasdaq

On April 15, 2020, we received a letter from The Nasdaq Stock Market (“Nasdaq”) noting that as a result of Matthew Pfeffer, a member of the board and chair of the audit committee of the board, being appointed as Acting Chief Executive Officer, the Company no longer complies with Nasdaq’s independent director and audit committee requirements set forth in Nasdaq Listing Rule 5605. Consistent with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4), Nasdaq will allow us a cure period in order to regain compliance as follows:

•

until the earlier of our next annual shareholders’ meeting or March 27, 2021; or

•

if the next annual shareholders’ meeting is held before September 23, 2020, then we must evidence compliance no later than September 23, 2020.

On June 1, 2020 (the “June Notification Date”), Nasdaq notified us that following the resignation of William J. Link, effective May 31, 2020, we are non-compliant with Nasdaq’s independent director and audit committee requirements as set forth in Listing Rule 5605 due to more than one vacancy on our board and audit committee. Nasdaq had previously notified us on April 15, 2020 that due to the appointment of Matt Pfeffer as Acting Chief Executive Officer of the Company, the Company no longer complied with the Listing Rules and that consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4) the Company was provided with a cure period described above in which to regain compliance. Nasdaq indicated that as a result of Mr. Link’s resignation we are no longer automatically eligible for the above described cure period and that the Company must submit a plan of compliance no later than July 16, 2020. If Nasdaq accepts our plan of compliance, we can be granted an extension of up to 180 calendar days from the June Notification Date to evidence compliance with the Listing Rules. If the plan is not accepted, we may appeal before a Nasdaq Hearing Panel.

On June 2, 2020, Nasdaq further notified us that as a result of Dr. Link’s resignation from the Company’s board and all committees thereof, effective May 31, 2020, we no longer comply with Nasdaq’s compensation committee requirements set forth in Listing Rule 5605.

However, consistent with Listing Rule 5605(d)(2) Nasdaq will provide us a cure period in order to regain compliance as follows:

•

until the earlier of our next annual shareholders’ meeting or May 31, 2021; or

•

if the next annual shareholders’ meeting is held before November 27, 2020, then we must evidence compliance no later than November 27, 2020.

We must submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance with the rules no later than as described above. If we do not regain compliance by the dates set forth above, Nasdaq will provide written notification to us that our securities will be delisted, at which time we may appeal the delisting determination to a Nasdaq Hearing Panel.

The Notice has no effect on the listing of our common stock at this time, and our common stock continues to trade on The Nasdaq Capital Market under the symbol “EYES.” We intend to regain compliance with the independent director, audit committee and compensation committee requirements under the Listing Rules however no assurance can be given that we will be able to regain compliance.

Employee Stock Purchase Plan

We completed our offer to rescind certain purchases of shares under our ESPP plan on May 27, 2020. We voluntarily offered to rescind the sale of shares of our common stock to employees who purchased those shares under the ESPP and to reimburse any losses upon the sale of our shares of our common stock for certain purchase periods because these shares may not have been exempt from registration under the Securities Act of 1933. The rescission of these share purchases resulted in the repurchase and cancelation of 39,467 shares of our common stock. The total cost for the repurchase of these shares and the reimbursement of any losses from the sale of such shares totaled approximately $270,000.

Equity Offering

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited 2019 financial statements and related notes included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (“SEC”) on March 19, 2020. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our products, plans and strategy for our business and related financing, contains forward-looking statements that involve risks and uncertainties, including statements regarding our expected financial results in future periods. The words “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “projects,” “will,” “would,” “strategy” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding expectations for revenues, liquidity, cash flows and financial performance, the anticipated results of our development efforts and the timing for receipt of required regulatory approvals, insurance reimbursements and product launches, our financing plans and future capital requirements, the materially adverse impact of the recent COVID-19 coronavirus pandemic and related public health measures on our business. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. You should read “Risk Factors” in Part II, Item 1A of this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. We assume no obligations to update these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report or to reflect actual outcomes.

Second Sight Medical Products, Inc. (NASDAQ: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. We are a recognized global leader in neuromodulation devices for blindness, and are committed to developing new technologies to treat the broadest populations of sight-impaired individuals.

Leveraging our 20 years of experience in neuromodulation for vision, we are developing the Orion^® Visual Cortical Prosthesis System (“Orion”), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including RP, glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. We are conducting a six-subject Early Feasibility Study of the Orion device at the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and Baylor College of Medicine in Houston (“Baylor”). Our 12 month results for the subjects indicate to us that:

•

We have a good safety profile. Three subjects experienced a total of eight adverse events (AEs) through the latest independent medical safety monitor meeting in December 2019 related to the device or to the surgery. One was considered a serious adverse event (SAE), and all of the adverse events were in the expected category. The one SAE was resolved quickly and did not require a hospital stay.

•

The efficacy data is encouraging. We measure efficacy by looking at three measures of visual function: The first is square localization, where Orion subjects sit in front of a touch screen and are asked to touch within the boundaries of a square when it appears. The second is direction of motion, where subjects are asked to identify the direction and motion of lines on a screen. The third is grating visual acuity, a measure of visual acuity that is adapted for very low vision. On square localization, five of the six subjects in our feasibility study performed significantly better with the system on than off. On direction of motion, all six performed better on than off; and on grating visual acuity, three had measurable visual acuity on the scale of this test (versus none who can do it with the device off). Another efficacy measurement of day-to-day functionality and benefit is FLORA, which stands for Functional Low-Vision Observer Rated Assessment. FLORA is an assessment performed by an independent, third-party low vision orientation and mobility specialist who spends time with each of the subjects in their homes. The specialist asks each of the subjects a series of questions and also observes them performing 15 or more daily living tasks, such as finding light sources, following a sidewalk, or sorting laundry. The specialist then determines if the system is providing a benefit, if it is neutral, or if it is actually hurting the abilities of subjects to perform these tasks. Our FLORA results show that for five of the six subjects, the Orion system is providing benefit. No peer-reviewed data is available yet for the Orion system. We reached agreement with the FDA in the fourth quarter of 2019 to utilize a revised version of FLORA as our primary efficacy endpoint in our pivotal trial for Orion, pending successful validation of the instrument.

Our principal offices are located in Los Angeles, California.

Our first commercially approved product, the Argus^® II Retinal Prosthesis System (“Argus II”), treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The Argus II was the only retinal prosthesis approved in the United States by the Food and Drug Administration (“FDA”), and was the first approved retinal prosthesis in the world. RP is a hereditary disease, affecting an estimated 1.5 million people worldwide including about 100,000 people in the United States, that causes a progressive degeneration of the light-sensitive cells of the retina, leading to significant visual impairment and ultimately blindness. A subset of these patients would be eligible for the Argus II since the approved baseline vision for the Argus II is worse than legally blind (20/200). We commissioned 3^rd party market research to estimate the size of the RP market that resulted in an estimate of approximately 1,500 patients in the US with advanced RP that could be treated with the Argus II given the eligibility criteria of our label. We no longer market the Argus II.

The Argus II system provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and there is no evidence that it can slow or reverse the progression of the disease. The majority of patients receive a significant benefit from the Argus II, however results can vary and some patients report receiving little or no benefit. By creating an artificial form of useful vision in patients who otherwise have total sight loss, the Argus II can provide benefits that include:

•

restoring independence through a renewed ability to navigate independently in unfamiliar environments;

•

improving patients’ orientation and mobility, such as locating doors and windows, avoiding obstacles, and following the lines of a crosswalk;

•

allowing patients to feel more connected with people in their surroundings, such as seeing when someone is approaching or moving away;

•

providing patients with enjoyment from being “visual” again, such as locating the moon, tracking groups of players as they move around a field, and watching moving streams of lights from fireworks;

•

enabling some patients to re-enter the workforce through multiple vocations that become possible because of Argus II; and

•

improving patients’ well-being and ability to perform activities of daily living

We began selling the Argus II System in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Given the limited addressable market of Argus II, we no longer market the Argus II and have focused all of our resources on the development of Orion.

We are also researching multiple technologies that we believe to be complimentary to artificial vision and could potentially provide significant enhancements to the Orion user experience. In most cases, we collaborate with 3^rd party firms to advance and integrate these innovative technologies with our artificial vision systems. Examples of technologies that we believe will be complimentary to our products include: eye tracking, object recognition and localization, thermal imaging and depth-based decluttering.

Recent developments

In March 2020, we were severely adversely impacted by the unprecedented economic shock caused by the COVID-19 pandemic and its related effects on our ability to secure financing for our planned activities. As a result, we significantly reduced our staff and expenses and conserved liquidity as we continue operations and explore strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not be in a related industry. We are actively seeking opportunities to develop partnerships or collaborations with others to advance further Orion development, conduct pivotal trials and bring the product to market for the treatment of blindness. No assurances can be given that any of these initiatives will occur.

In early March 2020, we commenced clinical validation activities for the FLORA-20 instrument, the primary efficacy endpoint we have selected for our future pivotal clinical trial of Orion. In mid-March 2020, our validation activities were suspended as a result of public health concerns and related social distancing due to COVID-19. We are in the process of evaluating when activities related to the validation study can be resumed.

On March 27, 2020, the Board of Directors appointed Matthew Pfeffer, a member of our Board and Chairman of the Audit Committee of the Board, as acting Chief Executive Officer. As a result, in April 2020, The Nasdaq Stock Market informed us, we no longer comply with Nasdaq’s independent director and audit committee requirements set forth in Nasdaq Listing Rule 5605. Nasdaq has also advised that in order to regain compliance we must submit a plan of compliance no later than July 16, 2020.

In furtherance of our decision to withdraw Argus II from the market, we have terminated two post-market studies for Argus II in Germany and the U.S., terminated an extended non-significant risk study in the U.S. for Argus 2s, suspended our technical support of Argus II worldwide, and withdrawn our submission to the FDA for market approval of the Argus 2s wearables system. In addition, we have reported to our notified body that we do not intend to distribute the Argus 2s in Europe or other markets, and will therefore let our CE Mark lapse for that product.

In May 2020, we completed an underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate gross proceeds of $7.5 million, and net proceeds of approximately $6.6 million after deducting underwriting discounts, commissions and other offering expenses. Based on our current plans, we believe the financing provides sufficient working capital to sustain approximately six months of ongoing operations.

In May 2020, we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”) to terminate our facility leases in which we agreed to vacate the premises by June 18, 2020 and pay $210,730 to bring our leases current and pay a one-time early termination fee of $150,000. Prior to the early termination, we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the respective remaining terms of our leases in February 2022 and April 2023.

As of June 10, 2020, we have reduced our employees to 10 individuals to focus on the advancement of Orion and sustain our ongoing operations.

Capital Funding

•

On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.6 million.

•

Issuances of common stock and warrants in a Rights Offering in February 2019 which provided $34.4 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2019 which provided $0.1 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the first quarter of 2018, which provided $4.0 million of net cash proceeds

•

Issuances of common stock via stock purchase agreements in May, August, October and December 2018, which provided net cash proceeds of $22.0 million

•

Revenue of $3.4 million and $6.9 million, for the years ended December 31, 2019 and 2018, respectively, generated by sales of our Argus II product

We received an award for $1.6 million grant (with the intent to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018. Our second year award was recently approved under this grant. As of March 31, 2020 we recorded $0.3 million of deferred grant costs associated with this grant which were offset with the related grant funds when received in April 2020.

On September 17, 2019, we received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (“SLAM”). This grant involves a joint collaboration with the Johns Hopkins University Applied Physics Laboratory, and is intended to speed the integration of SLAM into future generations of Orion. The goal is to give Orion users the ability to localize objects and navigate landmarks in unfamiliar surroundings in real time. APL is the primary recipient of the grant. We have suspended our activities on the project until we clarify our future plans.

In a rights offering completed on February 22, 2019 we sold approximately 5,976,000 units, each priced at $5.792 for net cash proceeds of approximately $34.4 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $11.76 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 5,180,000 units in the offering for an aggregate investment of approximately $30 million.

In November 2017, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we offered and sold, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold 278,000 shares of common stock for additional net proceeds of $4.0 million under the Sales Agreement. During December 2019, we sold approximately 17,000 shares of common stock which provided net proceeds of $0.1 million under the Sales Agreement. This agreement was terminated in April 2020.

We are subject to the risks and uncertainties associated with a business with no revenue that is developing a novel medical device. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. Based on our current plans, we do not have sufficient funds to continue operating our business at current levels for at least twelve months from the date of issuance of this report. To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. However, our operating plan may change as a result of many factors currently unknown to us, and we will need to seek additional funds during that period, through public or private equity offerings or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs, or we may be unable to expand or maintain our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations. Accordingly, these factors among others raise substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

Product and Clinical Development Plans

Orion. By further developing our visual cortical prosthesis, Orion, we believe we may be able to significantly expand our market to include nearly all profoundly blind individuals. The only notable exceptions for potential use of the Orion are those who are blind due to otherwise currently treatable diseases, individuals who are born blind, or blindness due to direct damage of the visual cortex, which is rare. However, of the estimated 36 million blind people worldwide, there are approximately 5.8 million people who are legally blind due to causes that are not otherwise treatable (including RP) or age-related macular degeneration (“AMD”). We continue to develop and refine our estimates of the potential addressable market size as we evaluate the commercial prospects for Orion using a combination of published sources, third party market research, and physician feedback. We currently estimate over 500,000 individuals in the US are legally blind due to retinitis pigmentosa, glaucoma, diabetic retinopathy, optic nerve disease and eye injury. Of this population, we estimate the potential US addressable market is between 50,000 and 100,000 individuals with bi-lateral blindness at the light-perception level or worse. Our marketing approvals by the FDA and other regulatory agencies will ultimately determine the subset of these patients who are eligible for the Orion based on our clinical trials and the associated results.

Our objective in designing and developing the Orion visual prosthesis system is to bypass the optic nerve and directly stimulate the part of the brain responsible for human vision. A six-subject Early Feasibility Study of the Orion device is currently underway at UCLA and Baylor. Our 12 month results for six of the subjects indicate a good safety profile with encouraging efficacy data and benefits in helping subjects perform their daily living tasks. We believe these data are encouraging and support advancement of Orion into a larger pivotal clinical study. Early promising results are not necessarily indicative of results which may be obtained in large clinical trials. No assurance can be given that we will achieve similar results in our larger Orion clinical trials. No peer-reviewed data is available yet for the Orion system.

In November 2017, the FDA granted Breakthrough Devices Program designation for the Orion. This designation is given to a few select medical devices in order to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions. This program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review.

COVID-19 Pandemic

In accordance with local and state guidelines regarding the COVID-19 pandemic, we are requiring all of our employees to work remotely unless they cannot perform their essential functions remotely, and have also suspended all non-essential travel for our employees. While many of our employees are accustomed to working remotely, much of our workforce has not historically been remote. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance becomes available, temporarily suspending travel and restricting the ability to do business in person may create operational or other challenges, any of which could harm our business, financial condition and results of operations.

In addition, our clinical trials have been affected by the COVID-19 outbreak. Patient visits in ongoing clinical trials have been delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. Also, some of our suppliers of certain materials used in the development of our product candidates are located in areas impacted by COVID-19 which could limit our ability to obtain sufficient materials for our product candidates. COVID-19 has and will continue to adversely affect global economies and financial markets, and may result in an economic downturn that could affect demand for our product candidates, if approved, and impact our operating results. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of the continued global economic impact of the pandemic. We cannot anticipate all of the ways in which health epidemics such as COVID-19 could adversely impact our business. Although we are continuing to monitor and assess the effects of the COVID-19 pandemic on our business, the ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. See the Risk Factors section for further discussion of the possible impact of the COVID-19 pandemic on our business.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States (“GAAP”) and the requirements of the United States Securities and Exchange Commission require management to make estimates, assumptions and judgments that affect the amounts, liabilities, revenue and expenses reported in the financial statements and the notes to the financial statements. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2019.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.

There have been no other material changes to our critical accounting policies during the three months ended March 31, 2020.

Results of Operations

Net sales. Our net sales consists of revenue primarily from the sale of our Argus II product which is no longer marketed. We do not expect future revenues from the sale of Argus II.

Cost of sales. Cost of sales includes the salaries, benefits, material, overhead, third party costs, warranty, charges for excess and obsolete inventory, and other costs required to make the Argus II system at our Los Angeles, California facility. Our product involves technologically complex materials and processes. We record cost of sales when products are implanted, which may differ from the period we are able to record revenue. Such timing differences may cause our reported results of operations to be difficult to compare from period to period.

Operating Expenses. We generally recognize our operating expenses as incurred in four general operational categories: research and development, clinical and regulatory, sales and marketing, and general and administrative. Our operating expenses also include a non-cash component related to the amortization of stock-based compensation for research and development, clinical and regulatory, sales and marketing, and general and administrative personnel. We have received grants from institutions or agencies, such as the National Institutes of Health, to help fund the some of the cost of our development efforts. We have recorded the amount of funding received from these grants as reductions to operating expenses.

•

Research and development expenses consist primarily of employee compensation and consulting costs related to the design, development, and enhancements of our current and potential future products, offset by grant revenue received in support of specific research projects. We expense our research and development costs as they are incurred. Due to the recent downsizing of our business, we are currently evaluating the path forward for our research and development activities for Orion, including the potential for collaboration with 3^rd parties and/or outsourcing the engineering work for Orion.

•

Clinical and regulatory expenses consist primarily of salaries, travel and related expenses for personnel engaged in clinical and regulatory functions, as well as internal and external costs associated with conducting clinical trials and maintaining relationships with regulatory agencies offset by grant revenue received in support of specific clinical research products. We expect clinical and regulatory expenses to be lower in the short-run as we have closed our clinical study activities related to Argus II and Orion clinical site visits have been temporarily put on hold due to COVID-19. In the long-run, we expect clinical and regulatory expenses to increase if and when we conduct a pivotal clinical study of Orion.

•

Sales and marketing expenses consist primarily of salaries, commissions, travel and related expenses for personnel engaged in sales, marketing, market access and business development functions, as well as costs associated with promotional and other marketing activities including the cost of units consumed as demos or samples. We expect sales and marketing expenses to be significantly lower in 2020 than in 2019 as we no longer employ sales and marketing personnel and no longer market the Argus II product.

•

General and administrative expenses consist primarily of salaries and related expenses for executive, legal, finance, human resources, information technology and administrative personnel, as well as recruiting and professional fees, patent filing and annuity costs, insurance costs and other general corporate expenses, including rent. We expect general and administrative expenses to be significantly lower in 2020 as we have significantly reduced staff.

Comparison of the Three Months Ended March 31, 2020 and 2019

We did not implant Argus II products during the first quarter of 2020 compared to 10 in the first quarter of 2019. Four of the implants were in Europe, the Middle East and Asia (collectively, “EMEA”) in the first quarter of 2019 while the remainder were in the U.S.

Net Sales. Net sales was zero in the first quarter of 2020 as compared to $1.1 million in the same period in 2019. Revenue was recognized for nine units in the first quarter of 2019. Revenue recognized per implant was approximately $113,000 in the first quarter of 2019. We do not expect future revenues from the sale of Argus II.

Cost of sales. Cost of sales was zero in the first quarter of 2020 as compared to $0.7 million in the first quarter of 2019. Cost of sales in the first quarter of 2019 consisted primarily of the cost of products implanted and unabsorbed production costs.

Research and development expense. Research and development expense increased by $1.7 million, or 78%, to $3.9 million in the first quarter of 2020 from $2.2 million in the first quarter of 2019. The costs increased from the prior period due primarily to costs incurred for internally produced prototypes. We expect our research and development expenses to decrease significantly in the short-run related to our reduction in force and significantly curtailed activity while we reevaluate our development plans.

Clinical and regulatory expense. Clinical and regulatory expense decreased $0.1 million, or 9%, to $0.9 million in the first quarter of 2020 from $1.0 million in the first quarter of 2019. This decrease is attributable to decreased costs associated with the Orion feasibility study. We expect clinical and regulatory costs to continue in the future at a reduced level as we resume activities for our Early Feasibility Study and reevaluate our development plans for Orion.

Selling and marketing expense. Selling and marketing expense decreased $1.4 million, or 67%, to $0.7 million in the first quarter of 2020 from $2.1 million in the first quarter of 2019. This decrease in costs was primarily driven by our reduced commercial activities related to Argus II and the resulting decreased use of outside services, supplies, reduced headcount and related compensation expense. We expect selling and marketing expense to decrease as we no longer market Argus II and are focused on Orion development.

General and administrative expense. General and administrative expense decreased $0.4 million, or 17%, to $2.0 million in the first quarter of 2020 from $2.4 million in the same period of 2019. This decrease is primarily attributable to lower compensation costs primarily due to reduced staffing. We expect general and administrative expenses to decrease related to our staffing reductions.

Restructuring charges. We recorded a non-cash restructuring charge of $2.4 million in the first quarter of 2019 to our reserve for excess and obsolete inventory in connection with our plans to suspend Argus II production. We recorded non-cash restructuring charges of $1.1 million in the first quarter of 2020 comprised of $0.4 million to fully reserve our inventory in connection with our decision to no longer market Argus II and $0.7 million to write-down our fixed assets that are not directly involved in the development of Orion and a $0.2 million cash charge for severance compensation all of which was settled in May 2020.

Liquidity and Capital Resources

Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing a novel medical device, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.

In a rights offering completed on February 22, 2019, we sold approximately 5,976,000 units, each priced at $5.792 for net cash proceeds of approximately $34.4 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $11.76 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 5,180,000 units in the offering for an aggregate investment of approximately $30 million. The expiration date of the warrants issued pursuant to this rights offering is March 14, 2024, and the expiration date of all previously outstanding warrants listed for trading under the symbol “EYESW” were extended to March 14, 2024.

On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.6 million. We believe the financing provides sufficient working capital to sustain approximately six months of ongoing operations.

We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of this report. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Conducting clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete and we may never generate the necessary data or results required to obtain marketing approval. We do not expect revenues until we are successful in completing the development and obtaining marketing approval for Orion. We expect expenses to increase in connection with our ongoing activities, particularly as we continue clinical trials of Orion, initiate new research and development projects and seek marketing approval for any product candidates that we successfully develop. In addition, if we obtain marketing approval for Orion, we expect to incur significant additional expenses related to sales, marketing, distribution and other commercial infrastructure to commercialize such product. In addition, our product candidates, if approved, may not achieve commercial success. We incur significant costs associated with operating as a public company in a regulated industry.

Until such time, if ever, we can generate substantial product revenues, we anticipate that we will seek to fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. Accordingly, these factors among others raise substantial doubt about our ability to continue as a going concern. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity, convertible debt or other equity-linked securities, the ownership interests of some or all of our common stockholders will be diluted, the holders of new equity securities may have priority rights over our existing stockholders and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If adequate funds are not available, we may be required to further curtail operations significantly or to obtain funds by entering into agreements on unattractive terms. If, for example, we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us. Our inability to raise capital could have a material adverse effect on our business, financial condition and results of operations. Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

Cash and cash equivalents decreased by $9.0 million from $11.3 million as of December 31, 2019 to $2.3 million as of March 31, 2020. Working capital was a deficit of $1.6 million as of March 31, 2020, as compared to $6.2 million as of December 31, 2019, a decrease of $7.8 million. We use our cash and cash equivalents and working capital to fund our operating activities.

Cash Flows from Operating Activities

During the first three months of 2020, we used $8.7 million of cash in operating activities, consisting primarily of a net loss of $8.9 million, offset by non-cash charges which provided cash of $1.5 million for depreciation and amortization of property and equipment, stock-based compensation, change in right of use assets, impairment charge and offset by a net change in operating assets and liabilities of $1.3 million. During the first three months of 2019, we used $7.2 million of cash in operating activities, consisting primarily of a net loss of $9.7 million, offset by non-cash charges which provided cash of $3.4 million for depreciation and amortization of property and equipment, stock-based compensation, change in right of use assets offset by a net change in operating assets and liabilities of $0.9 million.

Cash Flows from Investing Activities

Cash used for investing activities in the first three months of 2020 was $331,000 and was $37,000 in the first three months of 2019 both for the purchase of property and equipment.

Cash Flows from Financing Activities

Financing activities used $5,000 of cash in the first three months of 2020 consisting of $6,000 of net proceeds from the sale of common stock offset by the use of $11,000 for the repurchase of partial shares in connection with our reverse stock split. Financing activities provided $34.4 million of cash in the first three months of 2019 consisting of the net proceeds from the sale of common stock and warrants.

Off-Balance Sheet Arrangements

At March 31, 2020, we did not have any transactions, obligations or relationships that constitute off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity

The primary objective of our investment activities is to maintain the safety of principal and preserve liquidity without incurring significant risk. We invest cash in excess of our current needs in money market funds. As of March 31, 2020, our investments consisted solely of money market funds.

Exchange Rate Sensitivity

The majority of our operating expenses were denominated in U.S. dollars. We have not entered into foreign currency forward contracts to hedge our operating expense exposure to foreign currencies, but we may do so in the future.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our Acting Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. As of March 31, 2020, based on the evaluation of these disclosure controls and procedures, our CEO and CFO have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended March 31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We are updating our internal control environment to address changes in our risks in financial reporting to accommodate our reductions in operating activities, reductions in staffing levels, and segregation of duties. Such changes may result in new or reduced controls.

Inherent Limitations on Effectiveness of Controls

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II-OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time, we may be involved in a variety of legal proceedings and claims relating to securities laws, product liability, patent infringement, contract disputes, employment matters and other matters relating to various claims that arise in the normal course of our business in addition to governmental and other regulatory investigations and proceedings. It is our opinion that the outcome of such matters will not have a material adverse effect on our results of operations, however, the results of litigation, proceedings, disputes and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A.

Risk Factors

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report, including our financial statements and related notes, which could have a material adverse effect on our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, the impact of COVID-19 and any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.

In addition to other information set forth in this report, you should carefully consider the risk factors discussed under the “Risk Factors” section included in our 2019 Annual Report on Form 10-K, which was filed with the SEC on March 19, 2020 and as amended on Form 10-K/A and filed with the SEC on April 28, 2020, as well as those risk factors contained in our prospectus supplement dated April 30, 2020 as filed with the SEC on May 1, 2020. The information presented below updates, and should be read in conjunction with, the risk factors and information disclosed in our Form 10-K and our prospectus supplement.

Since we have a limited operating history and have no current revenue producing operations, it is difficult to evaluate the future of our business.

To date, our operations on a consolidated basis have consisted of the continued development and clinical studies of our Orion-focused technologies and implementation of the early parts of our business plan. We have incurred significant operating losses in each year since our inception and we will continue to incur additional losses for the next several years. In addition, our losses may be greater than expected and our operating results may suffer. We have limited historical financial data upon which we may base our projected revenue and base our planned operating expenses. Our limited operating history makes it difficult to evaluate our technology or prospective operations and business prospects.

Despite promising results from the Early Feasibility Study for Orion being conducted at UCLA and Baylor we currently have no commercial products or product revenue and may never become profitable.

To date, we have not generated profit from sales of our now discontinued Argus II product and will not generate revenues until we complete the development and attain the marketing approval for Orion. We have relied principally on financing from the sale of equity securities and the receipt of government and other grants to fund our operations. We expect that our future financial results will depend primarily on our success in further developing the Orion, conducting FDA approved clinical trials and obtaining clearance or approval for, launching, selling and supporting our Orion technology. To establish these operations we expect a need to expend significant resources on hiring of personnel, continued scientific and product research and development, potential product testing and pre-clinical and clinical investigation, intellectual property development and prosecution, marketing and promotion, capital expenditures, working capital, general and administrative expenses, and fees and expenses associated with our capital raising efforts. We expect to incur costs and expenses related to consulting costs, laboratory development costs, hiring of scientists, engineers, sales representatives and other

operational personnel, and the continued development of relationships with potential partners as we continue to seek regulatory clearance or approval for our products. We are incurring significant operating losses, we expect to continue to incur additional losses for at least the next several years, and we cannot assure you that we will generate revenue or be profitable in the future. Our future or updated Orion products may never be cleared or approved or become commercially viable or accepted for use.

Investment in medical device technology is highly speculative, because it entails substantial upfront capital expenditures and significant risk that any potential product will fail to demonstrate adequate efficacy, clinical utility or acceptance by physicians and blind individuals. Investors should evaluate an investment in us in light of the uncertainties encountered by developing medical technology companies in a competitive environment. There can be no assurance that our efforts will be successful or that we will ultimately be able to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could adversely affect the market price of our common stock and could significantly impair our ability to raise capital, expand our business or continue to implement our business plan.

There is substantial doubt about our ability to continue as a going concern.

To date, we have not generated any profit from our now discontinued Argus II product and we have incurred significant operating losses in each year since our inception and we anticipate continuing to incur additional losses for the next several years. In connection with our Annual Report on Form 10-K for the year ended December 31, 2019, management concluded that there is substantial doubt we can continue as an ongoing business for the next twelve months from the date that our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 were issued unless we obtain additional capital. As a result, our independent registered public accountants included an explanatory paragraph in their auditors’ report relating to going concern.

In May 2020 we sold 7.5 million shares of common stock at $1.00 per share to raise gross proceeds of $7.5 million in a registered public offering of securities. We plan to raise additional capital to fund our operations. No assurance can be given that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to us. Accordingly, management cannot conclude that such plans will be effectively implemented within the twelve months from the date that our unaudited condensed consolidated interim financial statements included in our Quarterly Report on Form 10-Q for the three months ended March 31, 2020 were issued.

These factors, combined with our forecast of cash required to fund operations for a period of at least twelve months from the date that unaudited condensed consolidated interim financial statements included in our Quarterly Report on Form 10-Q for the three months ended March 31, 2020 were issued, raise substantial doubt about our ability to continue as a going concern.

If we are unable to obtain sufficient funding, we may be unable to execute our business plan and fund operations. We may not be able to obtain additional financing on commercially reasonable terms, or at all.

We have experienced operating losses, and we may continue to incur operating losses for the next several years as we implement our business plan. Currently, we have no revenue and do not have arrangements in place for all the anticipated financing that would be required to fully implement our business plan. Our prior losses combined with expected future losses, have had and will continue to have, for the foreseeable future, an adverse effect on our stockholders’ equity and working capital.

We will need to raise additional capital in order to continue to execute our business plan in the future however there is no assurance that we will be successful, or that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to us. If we are unable to raise sufficient additional funds, we will need to further scale back our operations. The ongoing COVID-19 pandemic and resulting negative impact on the global macroeconomic environment and capital markets may make it more difficult for us to raise additional funds.

We cannot give any assurance that we will be able to obtain all the necessary funding that we may need. In addition, we believe that we will require additional capital in the future to fully develop our technologies and planned products to the stage of FDA approvals and a commercial launch. We have pursued and may pursue additional funding through various financing sources, including the private sale of our equity and debt securities, licensing fees for our technology, joint ventures with capital partners and project type financing. If we raise funds by issuing equity or equity-linked securities, dilution to some or all our stockholders will result. Any equity securities issued may also provide for rights, preferences, or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. We also may seek government-based financing, such as development and research grants. There can be no assurance that funds will be available on commercially reasonable terms, if at all.

The incurrence of indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish, or license to a third party on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might otherwise be able to achieve more favorable terms. In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us.

If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our Orion features updated products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products. If this were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited or we may be unable to continue operations, in which case you could lose your entire investment.

Our business may be adversely affected by health epidemics including the recent coronavirus outbreak.

•

inability to meet warranty obligations for our Argus II products;

•

reputational damages of the Company and its products;

•

inability to raise additional funds to finance and continue our operations;

•

inability to maintain adequate office laboratory facilities;

•

inability to retain and hire experienced personnel;

•

inability to finalize our plan for and enroll patients into our proposed pivotal clinical trial;

•

material delays or inability to complete development and commercialization of Orion;

•

inability to satisfy Nasdaq’s continued listing requirements and possible delisting; and

•

other uncertain events that may have negative impact effect on our operations.

Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

Clinical testing is expensive and can take several or more years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the clinical trial process. Success in nonclinical studies and early feasibility clinical studies does not ensure that expanded clinical trials that will be used to support regulatory submissions will be successful. These setbacks may be caused by, among other things, nonclinical findings made while clinical trials were underway, and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval or clearance for our product candidates.

Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publish interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.

Our efforts may never demonstrate the feasibility of our Orion technology.

Our research and development efforts remain subject to all of the risks associated with the development of new technology. Our Orion technology, though based on our FDA approved Argus II is not yet fully developed. Development of the underlying technology, including the further development and refinement of our Orion technology, may be affected by unanticipated technical or other problems, among other development and research issues, and the possible insufficiency of funds needed in order to complete development of these products or devices. Regulatory and clinical hurdles or challenges also may result in delays and cause us to incur additional expenses that may increase our need for capital and result in additional losses. If we cannot complete, or if we experience significant delays in developing our technology, applications or products for use by those patients who can benefit from vision restoration, particularly after incurring significant expenditures, our business may fail and investors may lose the entirety of their investment.

We may not become commercially viable if our ultimate commercialized products or related treatments fail to obtain an adequate level of reimbursement by Medicare and other third-party payers.

Although we were able to obtain adequate third party-payer reimbursement for our Argus II system, we believe that the commercial viability of our potential devices and products and related implant and post-implant treatments, and therefore our commercial success as a company, will be affected materially by the availability of government reimbursement and medical insurance coverage and reimbursement for newly approved medical therapies, technologies and devices. Insurance coverage and reimbursement are not assured. It typically takes a period of use in the marketplace before coverage and reimbursement are permanently established, if they are granted at all. In the U.S. and other jurisdictions in Europe and other regions, physicians and other healthcare providers generally rely on insurance coverage and reimbursement for their revenues, therefore this is an important factor in the overall commercialization plans of a proposed product and whether it will be accepted for use in the marketplace. We expect our products to be priced at levels not generally affordable by patients directly and therefore without insurance coverage and reimbursement for our planned products, we would expect to attain limited revenues, if any.

Medicare, Medicaid, health maintenance organizations and other third-party payers are increasingly attempting to contain healthcare costs by limiting both the scope of coverage and the level of reimbursement of new medical technologies and products, and as a result, they may not cover or provide adequate payment for the use of our planned Orion products. In order to obtain satisfactory reimbursement arrangements, we may have to agree to reduce the fee or sales price to one lower than initially planned. Each plan may separately require us to provide scientific and clinical support for the use of our products and, as a result, the coverage determination process is often a time-consuming and costly process with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all. Even if Medicare and other third-party payers decide to cover treatments involving our proposed devices and products, we cannot be certain that the reimbursement levels will be adequate. Accordingly, even if our planned products are approved for commercial sale, unless government and other third-party payers provide adequate coverage and reimbursement for our devices and products, some physicians and their patients may be discouraged from using them, and our sales would suffer.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.Exhibits

EXHIBIT INDEX

Exhibit No.		Exhibit Description

31.1		Certification of Principal Executive Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of Sarbanes-Oxley Act of 2002.*

31.2		Certification of Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certifications of Principal Executive Officer and Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS		XBRL Instant Document.*

101.SCH		XBRL Taxonomy Extension Schema Document.*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.*

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.*

101.LAB		XBRL Taxonomy Extension Label Linkbase Document.*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.*

*	Included herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Name	Title	Date

/s/ Matthew Pfeffer	Acting Chief Executive Officer and Director	June 26, 2020
Matthew Pfeffer	(Principal Executive Officer)

/s/ John T. Blake	Chief Financial Officer	June 26, 2020
John T. Blake	(Principal Financial and Accounting Officer)

EX-31.1 2 eyes-ex311_8.htm EX-31.1 eyes-ex311_8.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew Pfeffer, hereby certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 26, 2020	/s/ Matthew Pfeffer
	Matthew Pfeffer
	Acting Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 eyes-ex312_7.htm EX-31.2 eyes-ex312_7.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John T. Blake, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 26, 2020	/s/ John T. Blake
	John T. Blake
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 eyes-ex321_6.htm EX-32.1 eyes-ex321_6.htm

Exhibit 32.1

Certifications of Principal Executive Officer and Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), Matthew Pfeffer, Chief Executive Officer (Principal Executive Officer) and John T. Blake, Chief Financial Officer (Principal Financial and Accounting Officer) of Second Sight Medical Products, Inc. (the “Company”), each hereby certifies that, to the best of his knowledge:

The Quarterly Report of the Company on Form 10-Q (the “Report”) for the quarter ended March 31, 2020, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 26, 2020	/s/ Matthew Pfeffer
	Matthew Pfeffer
	Acting Chief Executive Officer
	(Principal Executive Officer)

	/s/ John T. Blake
	John T. Blake
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Second Sight Medical Products, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 eyes-20200331.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure eyes:Employee 0001266806 2020-01-01 2020-03-31 0001266806 2020-06-25 0001266806 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001266806 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001266806 2020-03-31 0001266806 2019-12-31 0001266806 2019-01-01 2019-03-31 0001266806 us-gaap:CommonStockMember 2018-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001266806 us-gaap:RetainedEarningsMember 2018-12-31 0001266806 2018-12-31 0001266806 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001266806 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001266806 us-gaap:CommonStockMember 2019-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001266806 us-gaap:RetainedEarningsMember 2019-03-31 0001266806 2019-03-31 0001266806 us-gaap:CommonStockMember 2019-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001266806 us-gaap:RetainedEarningsMember 2019-12-31 0001266806 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001266806 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001266806 us-gaap:CommonStockMember 2020-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001266806 us-gaap:RetainedEarningsMember 2020-03-31 0001266806 eyes:SecondSightSwitzerlandSarlMember 2020-03-31 0001266806 srt:ExecutiveOfficerMember eyes:SecondSightSwitzerlandSarlMember 2020-03-31 0001266806 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-05-05 2020-05-05 0001266806 eyes:RightOfferingMember 2019-02-01 2019-02-28 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2019-10-01 2019-12-31 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2018-01-01 2018-03-31 0001266806 eyes:StockPurchaseAgreementMember eyes:EntitesBeneficiallyOwnedByMrGreggWilliamsMember 2018-01-01 2018-12-31 0001266806 2019-01-01 2019-12-31 0001266806 2018-01-01 2018-12-31 0001266806 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2020-05-05 0001266806 us-gaap:GrantMember eyes:NationalInstitutesOfHealthMember 2020-01-01 2020-03-31 0001266806 2019-09-17 2019-09-17 0001266806 eyes:RightOfferingMember 2019-02-22 2019-02-22 0001266806 eyes:RightOfferingMember 2019-02-22 0001266806 eyes:RightOfferingMember us-gaap:CommonStockMember 2019-02-22 0001266806 eyes:RightOfferingMember us-gaap:WarrantMember 2019-02-22 0001266806 eyes:RightOfferingMember eyes:EntitesBeneficiallyOwnedByMrGreggWilliamsMember 2019-02-22 2019-02-22 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2018-01-01 2018-02-28 0001266806 eyes:AtMarketIssuanceSalesAgreementMember 2019-01-01 2019-12-31 0001266806 eyes:ArgusIIProductMember 2019-01-01 2019-03-31 0001266806 eyes:ArgusIIProductMember 2020-01-01 2020-03-31 0001266806 eyes:ArgusIIProductMember us-gaap:SubsequentEventMember 2020-05-30 2020-05-31 0001266806 eyes:SeveranceMember us-gaap:SubsequentEventMember 2020-05-30 2020-05-31 0001266806 us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-03-31 0001266806 us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerSevenMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001266806 eyes:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001266806 eyes:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001266806 eyes:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001266806 country:US 2019-01-01 2019-03-31 0001266806 country:IT 2019-01-01 2019-03-31 0001266806 country:KR 2019-01-01 2019-03-31 0001266806 eyes:SecondSightSwitzerlandSarlMember 2020-03-31 0001266806 eyes:SecondSightSwitzerlandSarlMember 2019-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001266806 eyes:InventoryMember 2020-01-01 2020-03-31 0001266806 eyes:LaboratoryEquipmentMember 2020-03-31 0001266806 eyes:LaboratoryEquipmentMember 2019-12-31 0001266806 eyes:ComputerHardwareAndSoftwareMember 2020-03-31 0001266806 eyes:ComputerHardwareAndSoftwareMember 2019-12-31 0001266806 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001266806 eyes:FurnitureFixturesAndEquipmentMember 2019-12-31 0001266806 eyes:FixedAssetsMember 2020-01-01 2020-03-31 0001266806 us-gaap:SubsequentEventMember eyes:LessorMember 2020-05-18 2020-05-18 0001266806 eyes:LessorMember 2020-03-31 0001266806 2019-06-04 0001266806 eyes:UnderwritersWithInitialPublicOfferingMember 2019-01-01 2019-03-31 0001266806 eyes:WarrantsIssuedInConnectionWithMarch2017RightsOfferingMember 2020-01-01 2020-03-31 0001266806 eyes:WarrantsIssuedInConnectionWithMarch2017RightsOfferingMember 2019-01-01 2019-03-31 0001266806 eyes:WarrantsIssuedInConnectionWithFebruary2019RightsOfferingMember 2020-01-01 2020-03-31 0001266806 eyes:WarrantsIssuedInConnectionWithFebruary2019RightsOfferingMember 2019-01-01 2019-03-31 0001266806 eyes:CommonStockOptionsMember 2020-01-01 2020-03-31 0001266806 eyes:CommonStockOptionsMember 2019-01-01 2019-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001266806 eyes:EmployeeStockPurchasePlanMember 2019-01-01 2019-03-31 0001266806 eyes:RightOfferingMember 2017-03-05 2017-03-06 0001266806 eyes:RightOfferingMember 2017-03-06 0001266806 eyes:RightOfferingMember 2020-03-31 0001266806 eyes:MarchTwoThousandSeventeenMember 2019-02-15 2019-02-15 0001266806 eyes:RightOfferingMember eyes:MarchTwoThousandSeventeenMember 2019-02-15 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenMember 2019-01-01 2019-12-31 0001266806 eyes:MarchTwoThousandSeventeenWarrantsBeforeExtensionMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsAfterExtensionMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsBeforeExtensionMember us-gaap:MeasurementInputPriceVolatilityMember 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsAfterExtensionMember us-gaap:MeasurementInputPriceVolatilityMember 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsBeforeExtensionMember us-gaap:MeasurementInputExpectedTermMember 2019-02-15 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsAfterExtensionMember us-gaap:MeasurementInputExpectedTermMember 2019-02-15 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsBeforeExtensionMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-02-15 0001266806 eyes:MarchTwoThousandSeventeenWarrantsAfterExtensionMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-02-15 0001266806 us-gaap:WarrantMember 2019-12-31 0001266806 us-gaap:WarrantMember 2020-03-31 0001266806 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001266806 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember 2019-12-31 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember 2020-01-01 2020-03-31 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember 2020-03-31 0001266806 us-gaap:EmployeeStockOptionMember eyes:The2011EquityIncentivePlanMember 2019-01-01 2019-12-31 0001266806 eyes:The2011EquityIncentivePlanMember 2020-03-31 0001266806 eyes:The2011EquityIncentivePlanMember 2019-01-01 2019-09-30 0001266806 eyes:The2011EquityIncentivePlanMember eyes:CertainEmployeesAndDirectorsMember 2020-01-01 2020-03-31 0001266806 eyes:The2011EquityIncentivePlanMember eyes:CertainEmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001266806 eyes:The2015EmployeeStockPurchasePlanMember 2020-03-31 0001266806 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001266806 eyes:ClinicalAndRegulatoryMember 2020-01-01 2020-03-31 0001266806 eyes:ClinicalAndRegulatoryMember 2019-01-01 2019-03-31 0001266806 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-03-31 0001266806 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-03-31 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001266806 2020-06-23 0001266806 srt:ChiefFinancialOfficerMember us-gaap:SubsequentEventMember 2020-05-13 0001266806 us-gaap:SubsequentEventMember srt:ChiefOperatingOfficerMember 2020-05-08 0001266806 us-gaap:SubsequentEventMember srt:ChiefOperatingOfficerMember 2020-05-08 2020-05-08 0001266806 eyes:EmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2020-05-27 2020-05-27 SECOND SIGHT MEDICAL PRODUCTS INC 0001266806 --12-31 Non-accelerated Filer Yes Yes false true false 10-Q 2020-03-31 2020 Q1 false 001-36747 CA 02-0692322 12744 San Fernando Road Suite 400 Sylmar 91342 818 833-5000 CA 23118233 Common Stock EYES NASDAQ Warrants EYESW NASDAQ true false

2339000

11327000

455000

1029000

400000

926000

299000

3665000

13110000

232000

1122000

2342000

7000 25000

3904000

16599000

1588000

1093000

1575000

1889000

885000

2698000

733000 707000

106000

237000

335000

5222000

6959000

2365000

5222000

9324000

264003000

264008000

48892000

48613000

-543000

-562000

-313670000

-304784000

-1318000

7275000

3904000

16599000

10000000

300000000

15657000

15643000

15657000

15643000

1128000

731000

397000

3887000

2183000

914000 1006000

701000

2103000

2021000

2449000

1381000

2424000

8904000

10165000

-8904000

-9768000

18000

68000

-8886000

-9700000

-0.57

-0.80

15649000

12071000

19000

-8000

-8867000

-9708000

9542000

229019000

44111000

-575000

-269471000

3084000

-144000

5976000 34399000 34399000

7000

1577000 -1577000

898000

-9700000

-8000

15525000

263418000

46586000

-583000

-280892000

28529000

15643000

264008000

48613000

-562000

-304784000

2000 11000 11000

1000

6000

15000

279000

-8886000

19000

15657000

264003000

48892000

-543000

-313670000

106000

99000

279000

898000

3000

6000

1115000

2424000

-455000

95000

112000

786000

610000

-236000

497000

297000

286000

-57000

-1813000

-609000

26000 84000

53000

-8654000

-7150000

331000

37000

-331000

-37000

6000 34399000

-5000

34399000

2000

-1000

-8988000

27211000

4471000

31682000

2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Reverse Stok Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020.   The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted. Significant Accounting Policies   Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.   Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.4 million related to inventory of Argus II in the three months ended March 31, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million. In addition, we recorded an impairment of $0.7 million to our fixed assets used primarily for Argus activities and $0.2 million in severance payments all of which were paid in May 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations.        Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extended differing levels of credit to our customers, and typically did not require collateral. Customer Concentration The following tables provide information about disaggregated revenue by service type, customer and geographical market. The following table shows our revenues by customer type during the three months ended March 31, 2020 and 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct customers</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect customers (distributors)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   During the three months ended March 31, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 6</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>   As of March 31, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Geographic Concentration During the three months ended March 31, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Korea</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>   Foreign Operations The accompanying condensed consolidated financial statements as of March 31, 2020 and December 31, 2019 include gross assets amounting to $1.0 million and $1.3 million, respectively, relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.

5. Selected Balance Sheet Detail Inventories, net Inventories consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,716</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,282</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,069</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for excess and obsolete inventory and impairment charge</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,804</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,559</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>     We recorded $2.4 million as an impairment charge during the three months ended March 31, 2019, related to our plans to suspend Argus II production. We recorded further impairment charges to our inventory of $0.5 million in the first quarter of 2020. Additionally, finished goods inventory amounting to approximately $0.75 million that we expect to use for our future warranty claims has been offset with the warranty accrual which is included in accrued expenses.   Property and equipment Property and equipment consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,724</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture, fixtures and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,778</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(421</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,122</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million related to our fixed assets used primarily for Argus activities. We have additionally reclassified $0.4 million as assets held-for-sale which represents the estimated fair value of fixed assets that we plan to sell through auction.   Contract Liabilities Contract liabilities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Consideration received in advance of revenue recognition</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Revenue recognized</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Product Warranties   A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2020 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Additions</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Settlements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60)</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Adjustments and other</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,515</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Less: Finished goods inventory expected to be used for future warranty claims</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(750)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> </tr> </table></div>   Allowance for Doubtful Accounts Allowance for doubtful accounts consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">  </td> </tr> </table></div> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Additions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Write-offs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> </table>  </div> Right-of-use assets and operating lease liabilities   We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments.     On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date not later than June 18, 2020 (“Accelerated Termination Date”). We agreed to pay the Landlord (i) $210,730 to bring the Leases current (the “Owed Rent”) and to remit (ii) a one-time early termination fee in the amount of $150,000 (the “Early Termination Amount”). Prior to the early termination agreed in this letter we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the term remaining under the Leases through the respective expiration dates in February 2022 and April 2023.  The Landlord acknowledged that as of the date of the Letter Agreement the Owed Rent and the Early Termination Amount constituted all amounts owing to the Landlord under the Leases. As a result of the letter agreement, we wrote down the right-of-use assets and extinguished related lease liabilities in the amounts of $2.3 million and $2.4 million, respectively. We have accrued an early termination fee of $150,000 which is included in accrued expenses and restructuring charges as of and for the three months ended March 31, 2020.                   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;width:18.62%; border-bottom:solid 0.75pt transparent;"> Assets</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;width:49.62%; border-bottom:solid 0.75pt transparent;"> Classification</td> <td colspan="2" valign="top" style="width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="top" style="width:2.22%;">  </td> <td colspan="2" valign="top" style="width:14.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="top" style="width:0.9%; border-bottom:solid 0.75pt #000000;">  </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">       Non-current assets </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Right-of-use assets</td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%; border-top:solid 0.75pt #000000;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:12.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="top" bgcolor="#CFF0FC" style="width:2.22%;">  </td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,342</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%; border-top:solid 0.75pt #000000;">  </td> </tr> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;"> Liabilities</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;">  </td> <td valign="top" style="width:1.12%;">  </td> <td valign="top" style="width:12.88%;">  </td> <td valign="top" style="width:2.22%;">  </td> <td valign="top" style="width:1.12%;">  </td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:13.32%;">  </td> <td valign="top" style="width:0.9%;">  </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">   Current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Current operating lease liabilities</td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:12.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</td> <td valign="top" bgcolor="#CFF0FC" style="width:2.22%;">  </td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%;">  </td> </tr> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">       Long term</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Long term operating lease liabilities</td> <td valign="top" style="width:1.12%;"> $</td> <td valign="top" style="width:12.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="top" style="width:2.22%;">  </td> <td valign="top" style="width:1.12%;"> $</td> <td valign="top" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,365</td> <td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%;">  </td> </tr> </table>  </div> The components of lease expense for the three months ended March 31, 2020 and 2019 were as follows (unaudited):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:68.22%;"></td> <td style="width:1.11%;"></td> <td style="width:13.31%;"></td> <td style="width:2%;"></td> <td style="width:1.11%;"></td> <td style="width:13.29%;"></td> <td style="width:0.54%;"></td> <td style="width:0.43%;"></td> </tr> <tr> <td valign="bottom" style=" border-bottom:solid 1pt transparent;white-space:nowrap;">  </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:1pt; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">months ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="top">  </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:1pt; border-bottom:solid 1pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">months ended March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC"> Lease expense:</td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000;">   </td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="bottom" bgcolor="#CFF0FC"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  </td> <td valign="bottom" bgcolor="#CFF0FC">  </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC">  </td> </tr> <tr> <td valign="bottom" style="padding-left:9pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> Operating lease expense</td> <td valign="bottom"> $</td> <td valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</td> <td valign="top">  </td> <td valign="bottom"> $</td> <td valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</td> <td colspan="2" valign="bottom">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:9pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;"> Short-term lease expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:1pt; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="top" bgcolor="#CFF0FC" style=" border-bottom:solid 1pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:solid 1pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:1pt; border-bottom:solid 1pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">  </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="bottom" style="padding-left:18pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;"> Total lease expense</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.5pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> $</td> <td valign="bottom" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</td> <td valign="top" style=" border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" style=" border-top:solid 1pt #000000; border-bottom:double 2.5pt #000000;"> $</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.5pt; border-top:solid 1pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;">  </td> </tr> </table>  </div> Cash paid for lease amounts included in the measurement of lease liabilities amounted to $121,000 and $117,000, respectively, during the three months ended March 31, 2020 and 2019.

8. Stock-Based Compensation A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(300</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.45</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding as of March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.34</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The estimated aggregate intrinsic value of stock options exercisable as of March 31, 2020 was zero. As of March 31, 2020, there was $1.8 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.59 years. During the three months ended March 31, 2020, we granted stock options to purchase 205,701 shares of common stock to certain employees. The options are exercisable for a period of ten years from the date of grant at $5.98  per share, which was the fair value of our common stock on the respective grant date. The options generally vest over a period of four years . The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be $0.8 million ($4.05 per share) using the following assumptions: expected term of 6.02 years, volatility of 78.0%, risk-free interest rate of 1.50%  and expected dividend rate of 0.0%. During the quarter ended March 31, 2020 approximately 300,000 options were canceled and expired resulting in a reduction of stock option expense for the period of approximately $167,000.  The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2020 (in thousands, except per share data):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and released</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of March 31, 2020, there was $0.1 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.89 years.       We adopted an employee stock purchase plan in June 2015 for all eligible employees. At March 31, 2020 the available number of shares that may be issued under the plan is 77,031. Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and regulatory</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Reverse Stok Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020.   The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.

Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.   Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.4 million related to inventory of Argus II in the three months ended March 31, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million. In addition, we recorded an impairment of $0.7 million to our fixed assets used primarily for Argus activities and $0.2 million in severance payments all of which were paid in May 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations.        Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.

The following table shows our revenues by customer type during the three months ended March 31, 2020 and 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct customers</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect customers (distributors)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

During the three months ended March 31, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 6</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div> As of March 31, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

During the three months ended March 31, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Korea</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>

Assets measured at fair value on a recurring basis are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020 (unaudited):</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,179</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,179</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,307</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,307</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Inventories consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,716</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,282</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,069</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for excess and obsolete inventory and impairment charge</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,804</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,559</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Property and equipment consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,724</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture, fixtures and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,778</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(421</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,122</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Contract liabilities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Consideration received in advance of revenue recognition</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Revenue recognized</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2020 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Additions</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Settlements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60)</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         Adjustments and other</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,515</td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Less: Finished goods inventory expected to be used for future warranty claims</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(750)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> </tr> </table></div>

Allowance for doubtful accounts consisted of the following (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">  </td> </tr> </table></div> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Additions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Write-offs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> </tr> </table></div>

<div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;width:18.62%; border-bottom:solid 0.75pt transparent;"> Assets</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;width:49.62%; border-bottom:solid 0.75pt transparent;"> Classification</td> <td colspan="2" valign="top" style="width:14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="top" style="width:2.22%;">  </td> <td colspan="2" valign="top" style="width:14.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="top" style="width:0.9%; border-bottom:solid 0.75pt #000000;">  </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">       Non-current assets </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Right-of-use assets</td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%; border-top:solid 0.75pt #000000;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:12.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="top" bgcolor="#CFF0FC" style="width:2.22%;">  </td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,342</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%; border-top:solid 0.75pt #000000;">  </td> </tr> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;"> Liabilities</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;">  </td> <td valign="top" style="width:1.12%;">  </td> <td valign="top" style="width:12.88%;">  </td> <td valign="top" style="width:2.22%;">  </td> <td valign="top" style="width:1.12%;">  </td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:13.32%;">  </td> <td valign="top" style="width:0.9%;">  </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">   Current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Current operating lease liabilities</td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:12.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</td> <td valign="top" bgcolor="#CFF0FC" style="width:2.22%;">  </td> <td valign="top" bgcolor="#CFF0FC" style="width:1.12%;"> $</td> <td valign="top" bgcolor="#CFF0FC" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%;">  </td> </tr> <tr> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:18.62%;">       Long term</td> <td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:49.62%;"> Long term operating lease liabilities</td> <td valign="top" style="width:1.12%;"> $</td> <td valign="top" style="width:12.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="top" style="width:2.22%;">  </td> <td valign="top" style="width:1.12%;"> $</td> <td valign="top" style="width:13.32%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,365</td> <td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:0pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:1.12%;">  </td> </tr> </table></div>

As of March 31, 2020 and 2019, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants issued to underwriter of initial public offering</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants issued in connection with March 2017 rights offering</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,706</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,706</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants issued in connection with February 2019 rights offering</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,976</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,976</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,975</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of warrants activity for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,682</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.76</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Issued</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">        Forfeited or expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.5%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants outstanding as of March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,682</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.76</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.96</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercisable as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,682</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.5%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.76</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.96</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(300</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.45</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding as of March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.34</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and regulatory</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

0.995

0.005

6600000

34400000

100000

4000000

22000000

3400000

6900000

us-gaap:ProductMember

7500000

1.00

1600000

6400000

300000

2400000 P4Y

5976000

5.792

34400000

11.76

5180000000000

30000000

0.030 278000 17000

4000000

100000

1-for-8

2400000

500000

700000

200000

946000

182000

0.23

0.15

0.13

0.12

0.10

0.35

0.33

0.32

0.60

0.23

0.10

1000000

1300000

2179000

11307000

823000

803000

1699000

1716000

1282000

2069000

3804000

4588000

3804000

3559000

500000

750000

584000

2724000

69000

1672000

304000

78000

653000

4778000

421000

3656000

700000

400000

335000

1575000

60000

1515000 -750000

765000

117000

0.10

2020-06-18

210730

150000

900000

2300000

2400000

150000

123000

121000

117000

200000000

300000000

100000

1706000

5976000

890000

1073000

25000

64000

56000

8597000

8975000

11.76

P5Y

1706000

11.76

P5Y

632

1.7 P2Y

1600000

2.50

2.49

P3Y29D P5Y29D

0.00

7682000

11.76

11.76 P4Y2M15D P3Y11M15D P3Y11M15D

984000

206000

300000

890000

517000

21.78

5.98

12.45

21.27

30.34

P7Y8M12D

P3Y1M13D

P2Y3D

1800000

P2Y7M2D

205701

P10Y

5.98

P4Y

800000

4.05

P6Y7D

0.780

0.0150

0.000

300000

167000

61000

15000

21000

25000

5.92

100000

P2Y10M20D

77031

47000

102000

187000

15000

34000

41000

130000

121000

500000

279000

898000

3000000

100000 471000 P12M 2020-04-17

39467

270000

7500000

EX-101.SCH 6 eyes-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Business Operations link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Concentration of Risk link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Selected Balance Sheet Detail link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Equity Securities link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Risk and Uncertainties link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Litigation, Claims and Assessments link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Concentration of Risk (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Selected Balance Sheet Detail (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Equity Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Organization and Business Operations - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Concentration of Risk - Schedule of Revenues by Customer Type (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Concentration of Risk - Schedule of Concentration of Risk (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Concentration of Risk - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Fair Value on a Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Selected Balance Sheet Detail - Schedule of Inventories (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Selected Balance Sheet Detail - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Selected Balance Sheet Detail - Schedule of Lease Costs (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Equity Securities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Equity Securities - Anti-dilutive Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Warrants - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Warrants - Summary of Warrants Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Risk and Uncertainties - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Litigation, Claims and Assessments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 eyes-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 eyes-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 eyes-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Information [Table] Document Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Common Stock [Member] Common Stock [Member] Warrant [Member] Warrant [Member] Document Information [Line Items] Document Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Address, State or Province Entity Address State Or Province Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Represents the information pertaining to deposits and other assets. Represents information pertaining to accrued clinical trial expenses. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable, net Accounts Receivable Net Current Inventories, net Inventory Net Assets held-for-sale Assets Held For Sale Not Part Of Disposal Group Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Right-of-use assets Operating Lease Right Of Use Asset Deposits and other assets Deposits And Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY) Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Accrued compensation expense Employee Related Liabilities Current Accrued clinical trial expenses Accrued Clinical Trial Expenses Current operating lease liabilities Operating Lease Liability Current Contract liabilities Contract With Customer Liability Current Total current liabilities Liabilities Current Long term operating lease liabilities Operating Lease Liability Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders’ equity (deficiency): Stockholders Equity [Abstract] Preferred stock, no par value, 10,000 shares authorized; none outstanding Preferred Stock Value Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,657 and 15,643 as of March 31, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity (deficiency) Stockholders Equity Total liabilities and stockholders’ equity (deficiency) Liabilities And Stockholders Equity Preferred stock, no par value (in dollars per share) Preferred Stock No Par Value Preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Common stock, no par value (in dollars per share) Common Stock No Par Value Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares issued (in shares) Common Stock Shares Issued Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Clinical and regulatory expense, net of grants. Income Statement [Abstract] Net sales Revenue From Contract With Customer Including Assessed Tax Cost of sales Cost Of Goods And Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development, net of grants Research And Development Expense Clinical and regulatory, net of grants Clinical And Regulatory Expense Net Of Grants Selling and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Restructuring charges Restructuring Charges Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest income Interest Income Operating Net loss Net Income Loss Net loss per common share – basic and diluted Earnings Per Share Basic And Diluted Weighted average common shares outstanding – basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive income (loss): Other Comprehensive Income Loss Before Tax Portion Attributable To Parent [Abstract] Foreign currency translation adjustments Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent Comprehensive loss Comprehensive Income Net Of Tax Stock issued during period shares common stock and warrants in connection with rights offering net of issuance costs. Stock issued during period value common stock and warrants in connection with rights offering net of issuance costs. Warrant modification. Repurchase of fractional shares in connection with reverse stock split in shares. Repurchase of fractional shares in connection with reverse stock split. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Accumulated Other Comprehensive Loss [Member] Accumulated Other Comprehensive Income [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Balance beginning Balance beginning (in shares) Adoption of ASC Topic 842-Leases (see note 2) Cumulative Effect Of New Accounting Principle In Period Of Adoption Repurchase of fractional shares in connection with reverse stock split Repurchase Of Fractional Shares In Connection With Reverse Stock Split Repurchase of Fractional Shares In Connection With Reverse Stock Split (In Shares) Repurchase Of Fractional Shares In Connection With Reverse Stock Split In Shares Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs Stock Issued During Period Value Common Stock And Warrants In Connection With Rights Offering Net Of Issuance Costs Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares) Stock Issued During Period Shares Common Stock And Warrants In Connection With Rights Offering Net Of Issuance Costs Issuance of shares of common stock Stock Issued During Period Value New Issues Issuance of shares of common stock, Shares Stock Issued During Period Shares New Issues Release of restricted stock units (shares) Stock Issued During Period Shares Restricted Stock Award Gross Warrants modification (see note 7) Warrant Modification Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Foreign currency translation adjustment Balance ending Balance ending (in shares) The increase (decrease) during the period in the carrying value of accrued clinical trial expenses reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). Proceeds from issuance of common stock and warrants. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Stock-based compensation Share Based Compensation Non-cash lease expense Operating Lease Expense Restructuring charges-inventory and fixed asset impairment Restructuring Costs And Asset Impairment Charges Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Accrued compensation expenses Increase Decrease In Employee Related Liabilities Accrued clinical trial expenses Increase Decrease Accrued Clinical Trial Expenses Contract liabilities Increase Decrease In Contract With Customer Liability Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Net proceeds from sale of common stock and/or warrants Proceeds From Issuance Of Common Stock And Warrants Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash And Cash Equivalents Cash and cash equivalents: Cash And Cash Equivalents Period Increase Decrease [Abstract] Net increase (decrease) Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Balance at beginning of period Balance at end of period Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Business Operations Nature Of Operations Notes to Financial Statements Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis Of Presentation And Significant Accounting Policies [Text Block] Risks And Uncertainties [Abstract] Concentration of Risk Concentration Risk Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Selected Balance Sheet Detail Supplemental Balance Sheet Disclosures [Text Block] Stockholders Equity Note [Abstract] Equity Securities Stockholders Equity Note Disclosure [Text Block] The entire disclosure for warrants. Warrants And Rights Note Disclosure [Abstract] Warrants Warrant Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Risk and Uncertainties. Risk and Uncertainties Risk And Uncertainties [Text Block] Disclosure Text Block [Abstract] Litigation, Claims and Assessments Legal Matters And Contingencies [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Significant Accounting Policies Basis Of Accounting Policy Policy [Text Block] Reverse stok split policy text block. Reverse Stok Split Reverse Stok Split Policy Policy [Text Block] Segment Reporting Segment Reporting Policy Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedules of Revenues by Customer Type Disaggregation Of Revenue Table [Text Block] Schedule of Concentration of Risk Schedules Of Concentration Of Risk By Risk Factor [Text Block] Schedule of Geographic Concentration of Risk in Revenue Revenue From External Customers By Geographic Areas Table [Text Block] Schedule of Fair Value, Assets Measured on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Inventories Schedule Of Inventory Current Table [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Schedule of Contract Liabilities Contract With Customer Asset And Liability Table [Text Block] Schedule of Activity in the Company's Warranty Liabilities Schedule Of Product Warranty Liability Table [Text Block] Schedule of allowance for doubtful accounts of accounts receivable. Schedule of Allowance for Doubtful Accounts Schedule Of Allowance For Doubtful Accounts Of Accounts Receivable Table [Text Block] Schedule of Lease Assets and Liabilities Operating Leases Of Lessee Disclosure [Text Block] Schedule of Lease Costs Lease Cost Table [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Warrant Activity Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Stock Unit (RSU) Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Organization and business operations. Organization and business operations. Organization And Business Operations [Table] Organization And Business Operations [Table] Ownership Ownership [Axis] Ownership Ownership [Domain] Represents the information pertaining to the Second Sight (Switzerland) Sarl. Second Sight (Switzerland) Sarl [Member] Second Sight Switzerland Sarl [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Executive Officer [Member] Executive Officer [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event [Member] EX-101.PRE 10 eyes-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R47.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs) shares in Thousands	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, number of awards (in shares) \| shares	61
Vested and released (in shares) \| shares	(15)
Forfeited/canceled, number of awards (in shares) \| shares	(21)
Outstanding, number of awards (in shares) \| shares	25
Outstanding, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 5.92
Vested and released, weighted average grant date fair value per share (in dollars per share) \| $ / shares	5.92
Forfeited/canceled, weighted average grant date fair value per share (in dollars per share) \| $ / shares	5.92
Outstanding, weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 5.92

XML 12 R43.htm IDEA: XBRL DOCUMENT

Warrants - Additional Information (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	Feb. 22, 2019 $ / shares shares	Feb. 15, 2019 shares	Mar. 06, 2017 $ / shares shares	Dec. 31, 2019 USD ($)	Mar. 31, 2020 USD ($) shares
March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants issued		1.7
Adjustment to additional paid-in capital and accumulated deficit \| $				$ 1,600
March 2017 Warrants Before Extension [Member] \| Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		2.50
March 2017 Warrants Before Extension [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		81
March 2017 Warrants Before Extension [Member] \| Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		3 years 29 days
March 2017 Warrants Before Extension [Member] \| Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		0.00
March 2017 Warrants After Extension [Member] \| Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		2.49
March 2017 Warrants After Extension [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		82
March 2017 Warrants After Extension [Member] \| Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		5 years 29 days
March 2017 Warrants After Extension [Member] \| Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		0.00
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable, intrinsic value \| $					$ 0
Right Offering [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon right offering	5,976,000		1,706,000
Share price (in dollars per share) \| $ / shares	$ 5.792		$ 11.76
Additional share price (in dollars per share) \| $ / shares	$ 11.76		$ 11.76
Term of warrants	5 years		5 years
Warrants to purchase shares of common stock					632
Right Offering [Member] \| March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Term of warrants		2 years

XML 13 R22.htm IDEA: XBRL DOCUMENT

Selected Balance Sheet Detail (Tables)

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Inventories

Inventories consisted of the following (in thousands):

	March 31,			December 31,
	2020			2019
Raw materials	$	823		$	803
Work in process		1,699			1,716
Finished goods		1,282			2,069
		3,804			4,588
Allowance for excess and obsolete inventory and impairment charge		(3,804	)		(3,559	)
Inventories, net	$	—		$	1,029

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

	March 31,			December 31,
	2020			2019
Laboratory equipment	$	584		$	2,724
Computer hardware and software		69			1,672
Leasehold improvements		—			304
Furniture, fixtures and equipment		—			78
		653			4,778
Accumulated depreciation and amortization		(421	)		(3,656	)
Property and equipment, net	$	232		$	1,122

Schedule of Contract Liabilities

Contract liabilities consisted of the following (in thousands):

Beginning balance as of December 31, 2019	$	335
Consideration received in advance of revenue recognition		—
Revenue recognized		—
Ending balance as of March 31, 2020	$	335

Schedule of Activity in the Company's Warranty Liabilities

A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2020 is presented below:

Beginning balance as of December 31, 2019	$	1,575
Additions		—
Settlements		(60)
Adjustments and other		—
Total		1,515
Less: Finished goods inventory expected to be used for future warranty claims		(750)
Ending balance as of March 31, 2020	$	765

Schedule of Allowance for Doubtful Accounts

Allowance for doubtful accounts consisted of the following (in thousands):

Beginning balance as of December 31, 2019	$	117
Additions		—
Write-offs		(117)
Ending balance as of March 31, 2020	$	—

Schedule of Lease Assets and Liabilities

Assets	Classification	March 31, 2020		December 31, 2019
Non-current assets	Right-of-use assets	$	—	$	2,342
Liabilities
Current	Current operating lease liabilities	$	106	$	237
Long term	Long term operating lease liabilities	$	—	$	2,365

Schedule of Lease Costs

The components of lease expense for the three months ended March 31, 2020 and 2019 were as follows (unaudited):


	For the three months ended March 31, 2020		For the three months ended March 31, 2019
Lease expense:
Operating lease expense	$	123	$	123
Short-term lease expense		—		—
Total lease expense	$	123	$	123

XML 14 R26.htm IDEA: XBRL DOCUMENT

Organization and Business Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	2 Months Ended	3 Months Ended				12 Months Ended
	May 05, 2020	Sep. 17, 2019	Feb. 22, 2019	Mar. 06, 2017	Feb. 28, 2019	Feb. 28, 2018	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Organization And Business Operations [Line Items]
Net sales									$ 1,128		$ 3,400	$ 6,900
Type of Revenue [Extensible List]											us-gaap:ProductMember	us-gaap:ProductMember
Deferred costs							$ 300
Received grant		$ 2,400
Grant received funding period		4 years
Grant [Member] \| National Institutes of Health [Member]
Organization And Business Operations [Line Items]
Net sales							1,600
Grant received funding							$ 6,400
Right Offering [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance or sale of equity, total			$ 34,400		$ 34,400
Number of shares issued upon right offering			5,976,000	1,706,000
Share price (in dollars per share)			$ 5.792	$ 11.76
Exercise price of exercisable warrant			$ 11.76
At Market Issuance Sales Agreement [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance or sale of equity, total						$ 4,000		$ 100		$ 4,000	$ 100
Sale of Stock, commission paid to agents, percentage of gross proceeds						3.00%
Issuance of shares of common stock in connection with ATM, net of expenses (in shares)						278,000					17,000
Common Stock [Member] \| Right Offering [Member]
Organization And Business Operations [Line Items]
Number of securities called by each warrant or right			1
Common Stock [Member] \| Subsequent Event [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance or sale of equity, total	$ 6,600
Number of shares issued upon right offering	7,500,000
Share price (in dollars per share)	$ 1.00
Warrant [Member] \| Right Offering [Member]
Organization And Business Operations [Line Items]
Number of securities called by each warrant or right			1
Entities Beneficially Owned by Mr. Gregg Williams [Member] \| Right Offering [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance or sale of equity, total			$ 30,000
Number of shares issued upon right offering			5,180,000,000,000
Entities Beneficially Owned by Mr. Gregg Williams [Member] \| Stock Purchase Agreement [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance or sale of equity, total												$ 22,000
Second Sight (Switzerland) Sarl [Member]
Organization And Business Operations [Line Items]
Noncontrolling interest, ownership percentage by parent							99.50%
Second Sight (Switzerland) Sarl [Member] \| Executive Officer [Member]
Organization And Business Operations [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners							0.50%

XML 15 R8.htm IDEA: XBRL DOCUMENT

Organization and Business Operations

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Business Operations

1. Organization and Business Operations

Liquidity and Going Concern

•

Issuance of shares of common stock on May 5, 2020 which provided net proceeds of approximately $6.6 million.

•

Issuance of common stock and warrants in a Rights Offering in February 2019 which provided $34.4 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2019 which provided $0.1 million of net cash proceeds

•

Issuances of common stock through our At Market Issuance Sales Agreement during the first quarter of 2018, which provided $4.0 million of net cash proceeds

•

Issuances of common stock via stock purchase agreements in May, August, October and December 2018, which provided net cash proceeds of $22.0 million

•

Revenue of $3.4 million and $6.9 million, for the years ended December 31, 2019 and 2018, respectively, generated by sales of our Argus II product

On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.6 million.

Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net sales		$ 1,128
Cost of sales		731
Gross profit		397
Operating expenses:
Research and development, net of grants	$ 3,887	2,183
Clinical and regulatory, net of grants	914	1,006
Selling and marketing	701	2,103
General and administrative	2,021	2,449
Restructuring charges	1,381	2,424
Total operating expenses	8,904	10,165
Loss from operations	(8,904)	(9,768)
Interest income	18	68
Net loss	$ (8,886)	$ (9,700)
Net loss per common share – basic and diluted	$ (0.57)	$ (0.80)
Weighted average common shares outstanding – basic and diluted	15,649	12,071

XML 17 R37.htm IDEA: XBRL DOCUMENT

Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Beginning balance as of December 31, 2019	$ 1,575
Settlements	(60)
Total	1,515
Less: Finished goods inventory expected to be used for future warranty claims	(750)
Ending balance as of March 31, 2020	$ 765

XML 18 R33.htm IDEA: XBRL DOCUMENT

Selected Balance Sheet Detail - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Raw materials	$ 823	$ 803
Work in process	1,699	1,716
Finished goods	1,282	2,069
Inventories, gross	3,804	4,588
Allowance for excess and obsolete inventory and impairment charge	$ (3,804)	(3,559)
Inventories, net		$ 1,029

XML 19 R10.htm IDEA: XBRL DOCUMENT

Concentration of Risk

3 Months Ended

Mar. 31, 2020

Risks And Uncertainties [Abstract]

Concentration of Risk

3. Concentration of Risk

Credit Risk

Customer Concentration

The following tables provide information about disaggregated revenue by service type, customer and geographical market.

The following table shows our revenues by customer type during the three months ended March 31, 2020 and 2019:

	Three Months Ended March 31,
	2020		2019
Direct customers	$	—	$	946
Indirect customers (distributors)		—		182
Total	$	—	$	1,128

During the three months ended March 31, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues:

	Three Months Ended March 31,
	2020			2019
Customer 1		—	%		23	%
Customer 2		—	%		15	%
Customer 3		—	%		13	%
Customer 4		—	%		12	%
Customer 5		—	%		12	%
Customer 6		—	%		10	%
Customer 7		—	%		10	%

As of March 31, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable:

	March 31, 2020			December 31, 2019
Customer 1		—	%		35	%
Customer 2		—	%		33	%
Customer 3		—	%		32	%

Geographic Concentration

During the three months ended March 31, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:

	Three Months Ended March 31,
	2020			2019
United States		—	%		60	%
Italy		—	%		23	%
Korea		—	%		10	%

Foreign Operations

XML 20 R14.htm IDEA: XBRL DOCUMENT

Warrants

3 Months Ended

Mar. 31, 2020

Warrants And Rights Note Disclosure [Abstract]

Warrants

7. Warrants

A summary of warrants activity for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).

	Number of Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in Years)
Warrants outstanding as of December 31, 2019		7,682	$	11.76		4.21
Issued		—
Exercised		—
Forfeited or expired		—
Warrants outstanding as of March 31, 2020		7,682	$	11.76		3.96
Warrants exercisable as of March 31, 2020		7,682	$	11.76		3.96

The warrants outstanding as of March 31, 2020 had no intrinsic value.

XML 21 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Work Force Reductions

Employment Agreements

Subsidiary Closure

In May 2020, we initiated the process to investigate the closure of our Swiss subsidiary due to our decision to cease marketing the Argus II product and to reduce operating expenses.

Nasdaq

•

until the earlier of our next annual shareholders’ meeting or March 27, 2021; or

•

if the next annual shareholders’ meeting is held before September 23, 2020, then we must evidence compliance no later than September 23, 2020.

However, consistent with Listing Rule 5605(d)(2) Nasdaq will provide us a cure period in order to regain compliance as follows:

•

until the earlier of our next annual shareholders’ meeting or May 31, 2021; or

•

if the next annual shareholders’ meeting is held before November 27, 2020, then we must evidence compliance no later than November 27, 2020.

Employee Stock Purchase Plan

Equity Offering

XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 142 303 1 false 71 0 false 5 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.secondsight.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsCurrentPeriodUnaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsCurrentPeriodUnauditedParenthetical Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficiencyUnaudited Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.secondsight.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 100070 - Disclosure - Organization and Business Operations Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureOrganizationAndBusinessOperations Organization and Business Operations Notes 8 false false R9.htm 100080 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndRecentAccountingPronouncements Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Notes 9 false false R10.htm 100090 - Disclosure - Concentration of Risk Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRisk Concentration of Risk Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurements Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100110 - Disclosure - Selected Balance Sheet Detail Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetail Selected Balance Sheet Detail Notes 12 false false R13.htm 100120 - Disclosure - Equity Securities Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureEquitySecurities Equity Securities Notes 13 false false R14.htm 100130 - Disclosure - Warrants Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureWarrants Warrants Notes 14 false false R15.htm 100140 - Disclosure - Stock-Based Compensation Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 100150 - Disclosure - Risk and Uncertainties Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureRiskAndUncertainties Risk and Uncertainties Notes 16 false false R17.htm 100160 - Disclosure - Litigation, Claims and Assessments Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureLitigationClaimsAndAssessments Litigation, Claims and Assessments Notes 17 false false R18.htm 100170 - Disclosure - Subsequent Events Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 100180 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.secondsight.com/20200331/taxonomy/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndRecentAccountingPronouncements 19 false false R20.htm 100190 - Disclosure - Concentration of Risk (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRiskTables Concentration of Risk (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRisk 20 false false R21.htm 100200 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureFairValueMeasurements 21 false false R22.htm 100210 - Disclosure - Selected Balance Sheet Detail (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailTables Selected Balance Sheet Detail (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetail 22 false false R23.htm 100220 - Disclosure - Equity Securities (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureEquitySecuritiesTables Equity Securities (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureEquitySecurities 23 false false R24.htm 100230 - Disclosure - Warrants (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureWarrantsTables Warrants (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureWarrants 24 false false R25.htm 100240 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensation 25 false false R26.htm 100250 - Disclosure - Organization and Business Operations - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureOrganizationAndBusinessOperationsAdditionalInformationDetails Organization and Business Operations - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 27 false false R28.htm 100270 - Disclosure - Concentration of Risk - Schedule of Revenues by Customer Type (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRiskScheduleOfRevenuesByCustomerTypeDetails Concentration of Risk - Schedule of Revenues by Customer Type (Details) Details 28 false false R29.htm 100280 - Disclosure - Concentration of Risk - Schedule of Concentration of Risk (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRiskScheduleOfConcentrationOfRiskDetails Concentration of Risk - Schedule of Concentration of Risk (Details) Details 29 false false R30.htm 100290 - Disclosure - Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcenrationOfRiskScheduleOfGeographicConcentrationOfRiskInRevenueDetails Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details) Details 30 false false R31.htm 100300 - Disclosure - Concentration of Risk - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureConcentrationOfRiskAdditionalInformationDetails Concentration of Risk - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements - Fair Value on a Recurring Basis (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsFairValueOnRecurringBasisDetails Fair Value Measurements - Fair Value on a Recurring Basis (Details) Details 32 false false R33.htm 100320 - Disclosure - Selected Balance Sheet Detail - Schedule of Inventories (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfInventoriesDetails Selected Balance Sheet Detail - Schedule of Inventories (Details) Details 33 false false R34.htm 100330 - Disclosure - Selected Balance Sheet Detail - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailAdditionalInformationDetails Selected Balance Sheet Detail - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfPropertyAndEquipmentDetails Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) Details 35 false false R36.htm 100350 - Disclosure - Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfContractLiabilitiesDetails Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) Details 36 false false R37.htm 100360 - Disclosure - Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfActivityInCompanySWarrantyLiabilitiesDetails Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) Details 37 false false R38.htm 100370 - Disclosure - Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfAllowanceForDoubtfulAccountsDetails Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) Details 38 false false R39.htm 100380 - Disclosure - Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfLeaseAssetsAndLiabilitiesDetails Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) Details 39 false false R40.htm 100390 - Disclosure - Selected Balance Sheet Detail - Schedule of Lease Costs (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSelectedBalanceSheetDetailScheduleOfLeaseCostsDetails Selected Balance Sheet Detail - Schedule of Lease Costs (Details) Details 40 false false R41.htm 100400 - Disclosure - Equity Securities - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureEquitySecuritiesAdditionalInformationDetails Equity Securities - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Equity Securities - Anti-dilutive Securities (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureEquitySecuritiesAntiDilutiveSecuritiesDetails Equity Securities - Anti-dilutive Securities (Details) Details 42 false false R43.htm 100420 - Disclosure - Warrants - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails Warrants - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Warrants - Summary of Warrants Activity (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsActivityDetails Warrants - Summary of Warrants Activity (Details) Details 44 false false R45.htm 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 45 false false R46.htm 100450 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitRSUActivityDetails Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) Details 47 false false R48.htm 100470 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-based Compensation Expense (Details) Details 48 false false R49.htm 100480 - Disclosure - Risk and Uncertainties - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureRiskAndUncertaintiesAdditionalInformationDetails Risk and Uncertainties - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Litigation, Claims and Assessments - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureLitigationClaimsAndAssessmentsAdditionalInformationDetails Litigation, Claims and Assessments - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.secondsight.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 51 false false All Reports Book All Reports eyes-20200331.xml eyes-20200331.xsd eyes-20200331_cal.xml eyes-20200331_def.xml eyes-20200331_lab.xml eyes-20200331_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 23 R36.htm IDEA: XBRL DOCUMENT

Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Beginning Balance	$ 335	$ 335	$ 335
Ending Balance	$ 335	$ 335	$ 335

XML 24 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Money Market Funds [Member] - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Money market funds	$ 2,179	$ 11,307
Level 1 [Member]
Money market funds	$ 2,179	$ 11,307

XML 25 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2020
Disclosure Text Block [Abstract]
Significant Accounting Policies	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Reverse Stok Split	Reverse Stok Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020. The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.
Segment Reporting	Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market. Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.4 million related to inventory of Argus II in the three months ended March 31, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million. In addition, we recorded an impairment of $0.7 million to our fixed assets used primarily for Argus activities and $0.2 million in severance payments all of which were paid in May 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations. Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

XML 26 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Cash equivalents, which includes money market funds, are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs.

Assets measured at fair value on a recurring basis are as follows (in thousands):

	Total		Level 1		Level 2		Level 3
March 31, 2020 (unaudited):
Money market funds	$	2,179	$	2,179	$	—	$	—
December 31, 2019:
Money market funds	$	11,307	$	11,307	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

	Number of Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in Years)
Options outstanding as of December 31, 2019		984		$	21.78		7.70
Granted		206		$	5.98
Exercised		—		$
Forfeited or expired		(300	)	$	12.45
Options outstanding as of March 31, 2020		890		$	21.27		3.12
Options exercisable as of March 31, 2020		517		$	30.34		2.01

The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2020 (in thousands, except per share data):

	Number of Shares			Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2019		61		$	5.92
Awarded		—			—
Vested and released		(15	)		5.92
Forfeited/canceled		(21	)		5.92
Outstanding as of March 31, 2019		25		$	5.92

As of March 31, 2020, there was $0.1 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.89 years.

We adopted an employee stock purchase plan in June 2015 for all eligible employees. At March 31, 2020 the available number of shares that may be issued under the plan is 77,031.

	Three Months Ended March 31,
	2020		2019
Cost of sales	$	—	$	47
Research and development		102		187
Clinical and regulatory		15		34
Selling and marketing		41		130
General and administrative		121		500
Total	$	279	$	898

XML 28 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 29 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2019
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 10 months 20 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 100,000
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of stock options exercisable	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 1,800,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 7 months 2 days
2011 Equity Incentive Plan \| Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	205,701
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value	$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 7 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	78.00%
Stock options canceled and expired	300,000
Stock option expense	$ 167,000
2011 Equity Incentive Plan \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	206,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.98
Stock options canceled and expired	300,000
2011 Equity Incentive Plan \| Employee Stock Option \| Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
The 2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	77,031

XML 30 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 31 R42.htm IDEA: XBRL DOCUMENT

Equity Securities - Anti-dilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	8,597	8,975
Underwriter's With Initial Public Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		100
Warrants Issued in Connection With March 2017 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,706	1,706
Warrants Issued in Connection With February 2019 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	5,976	5,976
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	890	1,073
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	25	64
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		56

XML 32 R23.htm IDEA: XBRL DOCUMENT

Equity Securities (Tables)

3 Months Ended

Mar. 31, 2020

Stockholders Equity Note [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	March 31,
	2020		2019
Common stock warrants issued to underwriter of initial public offering		—		100
Common stock warrants issued in connection with March 2017 rights offering		1,706		1,706
Common stock warrants issued in connection with February 2019 rights offering		5,976		5,976
Common stock options		890		1,073
Restricted stock units		25		64
Employee stock purchase plan		—		56
		8,597		8,975

XML 33 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions		3 Months Ended
	May 31, 2020	Mar. 31, 2020	Mar. 31, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split		1-for-8
Argus II Product [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge		$ 0.5	$ 2.4
Argus II Product [Member] \| Subsequent Event [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge	$ 0.7
Severance [Member] \| Subsequent Event [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Restructuring charges, settle	$ 0.2

XML 34 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (8,886)	$ (9,700)
Other comprehensive income (loss):
Foreign currency translation adjustments	19	(8)
Comprehensive loss	$ (8,867)	$ (9,708)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 35 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	Jun. 25, 2020
Document Information [Line Items]
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	0001266806
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity File Number	001-36747
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	02-0692322
Entity Address, Address Line One	12744 San Fernando Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Sylmar
Entity Address, Postal Zip Code	91342
City Area Code	818
Local Phone Number	833-5000
Entity Address, State or Province	CA
Entity Common Stock, Shares Outstanding		23,118,233
Document Quarterly Report	true
Document Transition Report	false
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	EYES
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	EYESW
Security Exchange Name	NASDAQ

EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 R9.htm IDEA: XBRL DOCUMENT v3.20.1

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements
3 Months Ended

Mar. 31, 2020

Disclosure Text Block [Abstract]

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements
2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Reverse Stok Split

On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020.

The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.

Significant Accounting Policies

Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual cortical prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.

Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.4 million related to inventory of Argus II in the three months ended March 31, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million. In addition, we recorded an impairment of $0.7 million to our fixed assets used primarily for Argus activities and $0.2 million in severance payments all of which were paid in May 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations.



Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.

Recently Issued Accounting Pronouncements

We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Equity Securities
3 Months Ended

Mar. 31, 2020

Stockholders Equity Note [Abstract]

Equity Securities
6. Equity Securities

Increase in Authorized Shares of Common Stock

On June 4, 2019, our shareholders approved an amendment to our restated articles of incorporation increasing our authorized no par value shares of common stock from 200 million to 300 million shares.

Potentially Dilutive Common Stock Equivalents

As of March 31, 2020 and 2019, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).

March 31,

2020

2019

Common stock warrants issued to underwriter of initial public offering

—

100

Common stock warrants issued in connection with March 2017 rights offering

1,706

1,706

Common stock warrants issued in connection with February 2019 rights offering

5,976

5,976

Common stock options

890

1,073

Restricted stock units

25

64

Employee stock purchase plan

—

56

8,597

8,975

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Litigation, Claims and Assessments
3 Months Ended

Mar. 31, 2020

Disclosure Text Block [Abstract]

Litigation, Claims and Assessments
10. Litigation, Claims and Assessments

Ten oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. We have filed one opposition that is currently pending in the European Patent Office challenging the validity of a patent owned by Pixium Vision. The outcome of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations.

By letter received June 23, 2020 counsel for a participant in the Orion Early Feasibility Study has alleged claims against the Company for breach of contract, breach of the implied covenant of good faith and fair dealing, negligent misrepresentation, promissory estoppel and negligent infliction of emotional distress. Counsel in addition has alleged that Second Sight has violated the protocol established by the FDA for good clinical practice within this industry. As full compensation for damages arising from these claims the Company was presented with a demand for payment of $3,000,000. The Company believes that the claims asserted are without merit. The Company will seek to deter the filing of this claim. However, these claims are in the early stage and no assurance can be given that this matter will not result in litigation. To the extent a lawsuit is filed, the Company intends to vigorously defend it.

We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136
+ Details

Name: us-gaap_LegalMattersAndContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R38.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2020

USD ($)

Allowance for Doubtful Accounts Receivable [Roll Forward]

Beginning balance as of December 31, 2019 $ 117

Write-offs $ (117)

X

- Definition
Amount of allowance for credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of direct write-downs of accounts receivable charged against the allowance.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 41 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail - Additional Information (Details) - USD ($)
3 Months Ended

May 31, 2020

May 18, 2020

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Product Information [Line Items]

Finished goods inventory expected to be used for future warranty claims $ (750,000)

Estimated incremental borrowing rate 10.00%

Non-cash lease expense $ 3,000 $ 6,000

Right-of-use assets $ 2,342,000

Operating Lease, Payments 121,000 117,000

Sylmar Biomedical Park, LLC (the “Landlord”) [Member]

Product Information [Line Items]

Right-of-use assets 2,300,000

Lease liability 2,400,000

Accrued termination fee 150,000

Subsequent Event [Member] | Sylmar Biomedical Park, LLC (the “Landlord”) [Member]

Product Information [Line Items]

Termination date of the lease Jun. 18, 2020

Non-cash lease expense $ 210,730

Early lease termination fee 150,000

Payments for base rent subject to early termination $ 900,000

Argus II Product [Member]

Product Information [Line Items]

Impairment charge 500,000 $ 2,400,000

Other assets impairment charge 700,000

Argus II Product [Member] | Subsequent Event [Member]

Product Information [Line Items]

Impairment charge $ 700,000

Inventory [Member]

Product Information [Line Items]

Impairment charge 500,000

Finished goods inventory expected to be used for future warranty claims 750,000

Fixed Assets [Member]

Product Information [Line Items]

Impairment charge $ 400,000

X

- Definition
Accrued termination fee.
+ References
No definition available.
+ Details

Name: eyes_AccruedTerminationFee

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Finished goods inventory expected to be used for future warranty claims.
+ References
No definition available.
+ Details

Name: eyes_FinishedGoodsInventoryExpectedToBeUsedOrFutureWarrantyClaims

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_AssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
+ Details

Name: us-gaap_GainLossOnContractTermination

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash payments to lessor's for use of assets under operating leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Stated interest rate of the subordinated debt.
+ References
No definition available.
+ Details

Name: us-gaap_SubordinatedBorrowingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=eyes_LessorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=eyes_ArgusIIProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=eyes_InventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=eyes_FixedAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details)
3 Months Ended

Mar. 31, 2019

United States

Concentration Risk [Line Items]

Geographic concentration 60.00%

Italy

Concentration Risk [Line Items]

Geographic concentration 23.00%

Korea

Concentration Risk [Line Items]

Geographic concentration 10.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_IT

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_KR

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R51.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events - Additional Information (Details)

May 27, 2020

USD ($)

shares

May 08, 2020

USD ($)

May 05, 2020

USD ($)

$ / shares

shares

May 13, 2020

USD ($)

Mar. 31, 2020

Employee

Subsequent Event [Line Items]

Number of retained employees | Employee 10

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued upon right offering | shares 7,500,000

Share price (in dollars per share) | $ / shares $ 1.00

Proceeds from issuance or sale of equity, total $ 6,600,000

Gross proceeds from issuance or sale of shares $ 7,500,000

Subsequent Event [Member] | Employee Stock Purchase Plan [Member]

Subsequent Event [Line Items]

Repurchase and cancelation of common stock, Shares | shares 39,467

Repurchase and cancelation of common stock, Value $ 270,000

Chief Financial Officer [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

One time bonus $ 100,000

Chief Operating Officer [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Termination payment $ 471,000

Maximum period for reimbursement of COBRA 12 months

Termination date Apr. 17, 2020

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
No definition available.
+ Details

Name: eyes_GrossProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum period for reimbursement of COBRA.
+ References
No definition available.
+ Details

Name: eyes_MaximumPeriodForReimbursementOfCOBRA

Namespace Prefix: eyes_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of retained employees
+ References
No definition available.
+ Details

Name: eyes_NumberOfRetainedEmployees

Namespace Prefix: eyes_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
One time bonus.
+ References
No definition available.
+ Details

Name: eyes_OneTimeBonus

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Termination date
+ References
No definition available.
+ Details

Name: eyes_TerminationDate

Namespace Prefix: eyes_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Termination payment.
+ References
No definition available.
+ Details

Name: eyes_TerminationPayment

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares that have been repurchased and retired during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=eyes_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R48.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Allocated share-based compensation expense $ 279 $ 898

Cost of Sales

Allocated share-based compensation expense 47

Research and Development

Allocated share-based compensation expense 102 187

Clinical and Regulatory

Allocated share-based compensation expense 15 34

Selling and Marketing

Allocated share-based compensation expense 41 130

General and Administrative

Allocated share-based compensation expense $ 121 $ 500

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=eyes_ClinicalAndRegulatoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R44.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants - Summary of Warrants Activity (Details) - Warrant [Member] - $ / shares
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Class of Warrant or Right, Outstanding [Roll Forward]

Outstanding at beginning 7,682,000

Outstanding at ending 7,682,000 7,682,000

Exercisable at ending 7,682,000

Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]

Outstanding at beginning $ 11.76

Outstanding at ending 11.76 $ 11.76

Exercisable at ending $ 11.76

Class of Warrant or Right, Weighted Average Remaining Contractual Life of Warrants or Rights [Roll Forward]

Outstanding at ending 3 years 11 months 15 days 4 years 2 months 15 days

Exercisable at ending 3 years 11 months 15 days

X

- Definition
Number of warrants exercisable
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightExercisable

Namespace Prefix: eyes_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Class of warrant or right exercise price of warrants or rights.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAbstract

Namespace Prefix: eyes_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or right outstanding.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightOutstandingAbstract

Namespace Prefix: eyes_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeExercisableOfWarrantsOrRights1

Namespace Prefix: eyes_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for warrant outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights1

Namespace Prefix: eyes_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or right weighted average remaining contractual life of warrants or rights.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsAbstract

Namespace Prefix: eyes_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights exercisable.
+ References
No definition available.
+ Details

Name: eyes_ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights

Namespace Prefix: eyes_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R40.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail - Schedule of Lease Costs (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Lease expense:

Operating lease expense $ 123 $ 123

Total lease expense $ 123 $ 123

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeaseCostAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R7.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash flows from operating activities:

Net loss $ (8,886) $ (9,700)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 106 99

Stock-based compensation 279 898

Non-cash lease expense 3 6

Restructuring charges-inventory and fixed asset impairment 1,115 2,424

Changes in operating assets and liabilities:

Accounts receivable 455 (95)

Inventories (112) (786)

Prepaid expenses and other assets (610) 236

Accounts payable 497 297

Accrued expenses 286 (57)

Accrued compensation expenses (1,813) (609)

Accrued clinical trial expenses 26 84

Contract liabilities 53

Net cash used in operating activities (8,654) (7,150)

Cash flows from investing activities:

Purchases of property and equipment (331) (37)

Net cash used in investing activities (331) (37)

Cash flows from financing activities:

Net proceeds from sale of common stock and/or warrants 6 34,399

Repurchase of fractional shares in connection with reverse stock split (11)

Net cash (used in) provided by financing activities (5) 34,399

Effect of exchange rate changes on cash and cash equivalents 2 (1)

Cash and cash equivalents:

Net increase (decrease) (8,988) 27,211

Balance at beginning of period 11,327 4,471

Balance at end of period $ 2,339 $ 31,682

X

- Definition
The increase (decrease) during the period in the carrying value of accrued clinical trial expenses reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: eyes_IncreaseDecreaseAccruedClinicalTrialExpenses

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock and warrants.
+ References
No definition available.
+ Details

Name: eyes_ProceedsFromIssuanceOfCommonStockAndWarrants

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Repurchase of fractional shares in connection with reverse stock split.
+ References
No definition available.
+ Details

Name: eyes_RepurchaseOfFractionalSharesInConnectionWithReverseStockSplit

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) - $ / shares

Mar. 31, 2020

Dec. 31, 2019

Statement Of Financial Position [Abstract]

Preferred stock, no par value (in dollars per share)

Preferred stock, shares authorized (in shares) 10,000,000 10,000,000

Preferred stock, shares outstanding (in shares) 0 0

Common stock, no par value (in dollars per share)

Common stock, shares authorized (in shares) 300,000,000 300,000,000

Common stock, shares issued (in shares) 15,657,000 15,643,000

Common stock, shares outstanding (in shares) 15,657,000 15,643,000

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements (Tables)
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets Measured on Recurring Basis
Assets measured at fair value on a recurring basis are as follows (in thousands):

Total

Level 1

Level 2

Level 3

March 31, 2020 (unaudited):

Money market funds

$

2,179

$

2,179

$

—

$

—

December 31, 2019:

Money market funds

$

11,307

$

11,307

$

—

$

—

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity
A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).

Number of

Shares

Weighted

Average

Exercise

Price

Per Share

Weighted

Average

Remaining

Contractual

Life (in Years)

Options outstanding as of December 31, 2019

984

$

21.78

7.70

Granted

206

$

5.98

Exercised

—

$

Forfeited or expired

(300

)

$

12.45

Options outstanding as of March 31, 2020

890

$

21.27

3.12

Options exercisable as of March 31, 2020

517

$

30.34

2.01

Summary of Restricted Stock Unit (RSU) Activity
The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2020 (in thousands, except per share data):

Number

of Shares

Weighted

Average Grant

Date Fair Value

Per Share

Outstanding as of December 31, 2019

61

$

5.92

Awarded

—

—

Vested and released

(15

)

5.92

Forfeited/canceled

(21

)

5.92

Outstanding as of March 31, 2019

25

$

5.92

Stock-based Compensation Expense
Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 was as follows (in thousands):

Three Months Ended

March 31,

2020

2019

Cost of sales

$

—

$

47

Research and development

102

187

Clinical and regulatory

15

34

Selling and marketing

41

130

General and administrative

121

500

Total

$

279

$

898

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Concentration of Risk - Schedule of Concentration of Risk (Details) - Customer Concentration Risk [Member]
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2019

Customer 1 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 23.00%

Customer 1 [Member] | Accounts Receivable [Member]

Concentration Risk [Line Items]

Customer concentration 35.00%

Customer 2 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 15.00%

Customer 2 [Member] | Accounts Receivable [Member]

Concentration Risk [Line Items]

Customer concentration 33.00%

Customer 3 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 13.00%

Customer 3 [Member] | Accounts Receivable [Member]

Concentration Risk [Line Items]

Customer concentration 32.00%

Customer 4 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 12.00%

Customer 5 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 12.00%

Customer 6 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 10.00%

Customer 7 [Member] | Sales Revenue, Net [Member]

Concentration Risk [Line Items]

Customer concentration 10.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=eyes_CustomerSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R45.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan - Employee Stock Option - $ / shares
shares in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Options outstanding, number of shares (in shares) 984

Granted, number of shares (in shares) 206

Forfeited or expired, number of shares (in shares) (300)

Options outstanding, number of shares (in shares) 890 984

Options exercisable, number of shares (in shares) 517

Options outstanding, weighted average exercise price (in dollars per share) $ 21.78

Granted, weighted average exercise price (in dollars per share) 5.98

Forfeited or expired, weighted average exercise price (in dollars per share) 12.45

Options outstanding, weighted average exercise price (in dollars per share) 21.27 $ 21.78

Options exercisable, weighted average exercise price (in dollars per share) $ 30.34

Options outstanding, weighted average remaining contractual life (Year) 3 years 1 month 13 days 7 years 8 months 12 days

Options exercisable, weighted average remaining contractual life (Year) 2 years 3 days

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=eyes_The2011EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.1

Equity Securities - Additional Information (Details) - $ / shares

Mar. 31, 2020

Dec. 31, 2019

Jun. 04, 2019

Mar. 31, 2019

Equity [Abstract]

Common stock, no par value (in dollars per share)

Common stock, shares authorized (in shares) 300,000,000 300,000,000 300,000,000 200,000,000

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R49.htm IDEA: XBRL DOCUMENT v3.20.1

Risk and Uncertainties - Additional Information (Details)

Mar. 31, 2020

Employee

Risks And Uncertainties [Abstract]

Number of retained employees 10

X

- Definition
Number of retained employees
+ References
No definition available.
+ Details

Name: eyes_NumberOfRetainedEmployees

Namespace Prefix: eyes_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 57 0001564590-20-030851-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-030851-xbrl.zip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end XML 58 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($)
$ in Thousands

Total

Common Stock [Member]

Accumulated Other Comprehensive Loss [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Balance beginning at Dec. 31, 2018 $ 3,084 $ 229,019 $ (575) $ 44,111 $ (269,471)

Balance beginning (in shares) at Dec. 31, 2018 9,542,000

Adoption of ASC Topic 842-Leases (see note 2) at Dec. 31, 2018 (144) (144)

Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs 34,399 $ 34,399

Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares) 5,976,000

Release of restricted stock units (shares) 7,000

Warrants modification (see note 7) 1,577 (1,577)

Stock-based compensation expense 898 898

Net loss (9,700) (9,700)

Foreign currency translation adjustment (8) (8)

Balance ending at Mar. 31, 2019 28,529 $ 263,418 (583) 46,586 (280,892)

Balance ending (in shares) at Mar. 31, 2019 15,525,000

Balance beginning at Dec. 31, 2019 $ 7,275 $ 264,008 (562) 48,613 (304,784)

Balance beginning (in shares) at Dec. 31, 2019 15,643,000 15,643,000

Repurchase of fractional shares in connection with reverse stock split $ (11) $ (11)

Repurchase of Fractional Shares In Connection With Reverse Stock Split (In Shares) (2,000)

Issuance of shares of common stock 6 $ 6

Issuance of shares of common stock, Shares 1,000

Release of restricted stock units (shares) 15,000

Stock-based compensation expense 279 279

Net loss (8,886) (8,886)

Foreign currency translation adjustment 19 19

Balance ending at Mar. 31, 2020 $ (1,318) $ 264,003 $ (543) $ 48,892 $ (313,670)

Balance ending (in shares) at Mar. 31, 2020 15,657,000 15,657,000

X

- Definition
Repurchase of fractional shares in connection with reverse stock split.
+ References
No definition available.
+ Details

Name: eyes_RepurchaseOfFractionalSharesInConnectionWithReverseStockSplit

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Repurchase of fractional shares in connection with reverse stock split in shares.
+ References
No definition available.
+ Details

Name: eyes_RepurchaseOfFractionalSharesInConnectionWithReverseStockSplitInShares

Namespace Prefix: eyes_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock issued during period shares common stock and warrants in connection with rights offering net of issuance costs.
+ References
No definition available.
+ Details

Name: eyes_StockIssuedDuringPeriodSharesCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts

Namespace Prefix: eyes_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock issued during period value common stock and warrants in connection with rights offering net of issuance costs.
+ References
No definition available.
+ Details

Name: eyes_StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrant modification.
+ References
No definition available.
+ Details

Name: eyes_WarrantModification

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 59 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets:

Cash and cash equivalents $ 2,339 $ 11,327

Accounts receivable, net 455

Inventories, net 1,029

Assets held-for-sale 400

Prepaid expenses and other current assets 926 299

Total current assets 3,665 13,110

Property and equipment, net 232 1,122

Right-of-use assets 2,342

Deposits and other assets 7 25

Total assets 3,904 16,599

Current liabilities:

Accounts payable 1,588 1,093

Accrued expenses 1,575 1,889

Accrued compensation expense 885 2,698

Accrued clinical trial expenses 733 707

Current operating lease liabilities 106 237

Contract liabilities 335 335

Total current liabilities 5,222 6,959

Long term operating lease liabilities 2,365

Total liabilities 5,222 9,324

Commitments and contingencies

Stockholders’ equity (deficiency):

Preferred stock, no par value, 10,000 shares authorized; none outstanding

Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,657 and 15,643 as of March 31, 2020 and December 31, 2019, respectively 264,003 264,008

Additional paid-in capital 48,892 48,613

Accumulated other comprehensive loss (543) (562)

Accumulated deficit (313,670) (304,784)

Total stockholders’ equity (deficiency) (1,318) 7,275

Total liabilities and stockholders’ equity (deficiency) $ 3,904 $ 16,599

X

- Definition
Represents information pertaining to accrued clinical trial expenses.
+ References
No definition available.
+ Details

Name: eyes_AccruedClinicalTrialExpenses

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the information pertaining to deposits and other assets.
+ References
No definition available.
+ Details

Name: eyes_DepositsAndOtherAssets

Namespace Prefix: eyes_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 15
-Paragraph 4
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220
+ Details

Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Concentration of Risk - Schedule of Revenues by Customer Type (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Concentration Risk [Line Items]

Revenue $ 1,128 $ 3,400 $ 6,900

Direct Customers [Member]

Concentration Risk [Line Items]

Revenue 946

Indirect Customers (Distributors) [Member]

Concentration Risk [Line Items]

Revenue $ 182

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Concentration of Risk (Tables)
3 Months Ended

Mar. 31, 2020

Risks And Uncertainties [Abstract]

Schedules of Revenues by Customer Type
The following table shows our revenues by customer type during the three months ended March 31, 2020 and 2019:

Three Months Ended

March 31,

2020

2019

Direct customers

$

—

$

946

Indirect customers (distributors)

—

182

Total

$

—

$

1,128

Schedule of Concentration of Risk
During the three months ended March 31, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues:

Three Months Ended

March 31,

2020

2019

Customer 1

—

%

23

%

Customer 2

—

%

15

%

Customer 3

—

%

13

%

Customer 4

—

%

12

%

Customer 5

—

%

12

%

Customer 6

—

%

10

%

Customer 7

—

%

10

%

As of March 31, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable:

March 31,

2020

December 31,

2019

Customer 1

—

%

35

%

Customer 2

—

%

33

%

Customer 3

—

%

32

%

Schedule of Geographic Concentration of Risk in Revenue
During the three months ended March 31, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:

Three Months Ended

March 31,

2020

2019

United States

—

%

60

%

Italy

—

%

23

%

Korea

—

%

10

%

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599
+ Details

Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants (Tables)
3 Months Ended

Mar. 31, 2020

Warrants And Rights Note Disclosure [Abstract]

Summary of Warrant Activity
A summary of warrants activity for the three months ended March 31, 2020 is presented below (in thousands, except per share and contractual life data).

Number of

Shares

Weighted

Average

Exercise

Price

Per Share

Weighted

Average

Remaining

Contractual

Life (in Years)

Warrants outstanding as of December 31, 2019

7,682

$

11.76

4.21

 Issued

—

 Exercised

—

 Forfeited or expired

—

Warrants outstanding as of March 31, 2020

7,682

$

11.76

3.96

Warrants exercisable as of March 31, 2020

7,682

$

11.76

3.96

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail
3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Selected Balance Sheet Detail
5. Selected Balance Sheet Detail

Inventories, net

Inventories consisted of the following (in thousands):

March 31,

December 31,

2020

2019

Raw materials

$

823

$

803

Work in process

1,699

1,716

Finished goods

1,282

2,069

3,804

4,588

Allowance for excess and obsolete inventory and impairment charge

(3,804

)

(3,559

)

Inventories, net

$

—

$

1,029

We recorded $2.4 million as an impairment charge during the three months ended March 31, 2019, related to our plans to suspend Argus II production. We recorded further impairment charges to our inventory of $0.5 million in the first quarter of 2020. Additionally, finished goods inventory amounting to approximately $0.75 million that we expect to use for our future warranty claims has been offset with the warranty accrual which is included in accrued expenses.

Property and equipment

Property and equipment consisted of the following (in thousands):

March 31,

December 31,

2020

2019

Laboratory equipment

$

584

$

2,724

Computer hardware and software

69

1,672

Leasehold improvements

—

304

Furniture, fixtures and equipment

—

78

653

4,778

Accumulated depreciation and amortization

(421

)

(3,656

)

Property and equipment, net

$

232

$

1,122

As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million related to our fixed assets used primarily for Argus activities. We have additionally reclassified $0.4 million as assets held-for-sale which represents the estimated fair value of fixed assets that we plan to sell through auction.

Contract Liabilities

Contract liabilities consisted of the following (in thousands):

Beginning balance as of December 31, 2019

$

335

 Consideration received in advance of revenue recognition

—

 Revenue recognized

—

Ending balance as of March 31, 2020

$

335

Product Warranties

A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2020 is presented below:

Beginning balance as of December 31, 2019

$

1,575

 Additions

—

 Settlements

(60)

 Adjustments and other

—

 Total

1,515

 Less: Finished goods inventory expected to be used for future warranty claims

(750)

Ending balance as of March 31, 2020

$

765

Allowance for Doubtful Accounts

Allowance for doubtful accounts consisted of the following (in thousands):

Beginning balance as of December 31, 2019

$

117

 Additions

—

 Write-offs

(117)

Ending balance as of March 31, 2020

$

—

Right-of-use assets and operating lease liabilities

We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments.

On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date not later than June 18, 2020 (“Accelerated Termination Date”). We agreed to pay the Landlord (i) $210,730 to bring the Leases current (the “Owed Rent”) and to remit (ii) a one-time early termination fee in the amount of $150,000 (the “Early Termination Amount”). Prior to the early termination agreed in this letter we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the term remaining under the Leases through the respective expiration dates in February 2022 and April 2023. The Landlord acknowledged that as of the date of the Letter Agreement the Owed Rent and the Early Termination Amount constituted all amounts owing to the Landlord under the Leases. As a result of the letter agreement, we wrote down the right-of-use assets and extinguished related lease liabilities in the amounts of $2.3 million and $2.4 million, respectively. We have accrued an early termination fee of $150,000 which is included in accrued expenses and restructuring charges as of and for the three months ended March 31, 2020.

Assets

Classification

March 31,

2020

December 31,
2019

 Non-current assets

Right-of-use assets

$

—

$

2,342

Liabilities

 Current

Current operating lease liabilities

$

106

$

237

 Long term

Long term operating lease liabilities

$

—

$

2,365

The components of lease expense for the three months ended March 31, 2020 and 2019 were as follows (unaudited):

For the three

months ended

March 31,

2020

For the three

months ended
March 31,

2019

Lease expense:





Operating lease expense

$

123

$

123

Short-term lease expense

—

—

Total lease expense

$

123

$

123

Cash paid for lease amounts included in the measurement of lease liabilities amounted to $121,000 and $117,000, respectively, during the three months ended March 31, 2020 and 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Risk and Uncertainties
3 Months Ended

Mar. 31, 2020

Risks And Uncertainties [Abstract]

Risk and Uncertainties
9. Risk and Uncertainties

In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread globally. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, most states in the U.S., including California, where we are headquartered, have declared a state of emergency. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns.

In accordance with local and state guidelines regarding the COVID-19 pandemic, we are requiring all of our employees to work remotely unless they cannot perform their essential functions remotely, and have also suspended all non-essential travel for our employees. While a significant number of our employees may be accustomed to working remotely or working with other remote employees, much of our workforce has not historically been remote. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance becomes available, temporarily suspending travel and restricting the ability to do business in person may create operational or other challenges, any of which could harm our business, financial condition and results of operations.

In addition, our clinical trials may be affected by the COVID-19 outbreak. Patient visits in ongoing clinical trials may be delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. For example, scheduled patient visits to our clinical sites at UCLA and Baylor were temporarily put on hold due to COVID-19 and we are in the process of planning to resume patient visits with the sites. In addition, the validation study for the revised FLORA assessment was paused due to travel requirements for its completion. Also, some of our suppliers of certain materials used in the development of our product candidates are located in areas impacted by COVID-19 which could limit our ability to obtain sufficient materials for our product candidates. COVID-19 has and will continue to adversely affect global economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our product candidates, if approved, and impact our operating results. Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of the continued global economic impact of the pandemic. We could experience further harm to our business and we cannot anticipate all of the ways in which health epidemics such as COVID-19 could adversely impact our business. Although we are continuing to monitor and assess the effects of the COVID-19 pandemic on our business, the ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change.

COVID-19 has directly and indirectly adversely affected Second Sight and will likely continue to do so for an uncertain period of time. In March and April 2020 we laid off a substantial majority of our employees as a result of COVID-19 and an inability to obtain financing. We retain approximately 10 of our employees to oversee current operations. The cumulative effects of COVID-19 on the Company cannot be predicted at this time, but could include, without limitation:

•

inability to meet warranty obligations for our Argus II products;

•

reputational damages of the Company and its products;

•

inability to raise additional funds to finance and continue our operations;

•

inability to maintain adequate office laboratory facilities;

•

inability to retain and hire experienced personnel;

•

inability to finalize our plan for and enroll patients into our proposed pivotal clinical trial;

•

material delays or inability to complete development and commercialization of Orion;

•

inability to satisfy Nasdaq’s continued listing requirements and possible delisting; and

•

other uncertain events that may have negative impact effect on our operations.

X

- Definition
Risk and Uncertainties.
+ References
No definition available.
+ Details

Name: eyes_RiskAndUncertaintiesTextBlock

Namespace Prefix: eyes_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R35.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Property Plant And Equipment [Line Items]

Property and equipment, gross $ 653 $ 4,778

Accumulated depreciation and amortization (421) (3,656)

Property and equipment, net 232 1,122

Laboratory Equipment [Member]

Property Plant And Equipment [Line Items]

Property and equipment, gross 584 2,724

Computer Hardware and Software [Member]

Property Plant And Equipment [Line Items]

Property and equipment, gross $ 69 1,672

Leasehold Improvements [Member]

Property Plant And Equipment [Line Items]

Property and equipment, gross 304

Furniture, Fixtures and Equipment [Member]

Property Plant And Equipment [Line Items]

Property and equipment, gross $ 78

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_LaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_ComputerHardwareAndSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyes_FurnitureFixturesAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R31.htm IDEA: XBRL DOCUMENT v3.20.1

Concentration of Risk - Additional Information (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Concentration Risk [Line Items]

Assets $ 3,904 $ 16,599

Second Sight (Switzerland) Sarl [Member]

Concentration Risk [Line Items]

Assets $ 1,000 $ 1,300

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=eyes_SecondSightSwitzerlandSarlMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R39.htm IDEA: XBRL DOCUMENT v3.20.1

Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

ASSETS

Right-of-use assets $ 2,342

Liabilities

Current operating lease liabilities $ 106 237

Long term operating lease liabilities $ 2,365

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 68 R50.htm IDEA: XBRL DOCUMENT v3.20.1

Litigation, Claims and Assessments - Additional Information (Details)

Jun. 23, 2020

USD ($)

Disclosure Text Block [Abstract]

Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net $ 3,000,000

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 4B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438
+ Details

Name: us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance as of December 31, 2019	$ 117
Write-offs	$ (117)

Selected Balance Sheet Detail - Additional Information (Details) - USD ($)			3 Months Ended
	May 31, 2020	May 18, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Product Information [Line Items]
Finished goods inventory expected to be used for future warranty claims			$ (750,000)
Estimated incremental borrowing rate			10.00%
Non-cash lease expense			$ 3,000	$ 6,000
Right-of-use assets					$ 2,342,000
Operating Lease, Payments			121,000	117,000
Sylmar Biomedical Park, LLC (the “Landlord”) [Member]
Product Information [Line Items]
Right-of-use assets			2,300,000
Lease liability			2,400,000
Accrued termination fee			150,000
Subsequent Event [Member] \| Sylmar Biomedical Park, LLC (the “Landlord”) [Member]
Product Information [Line Items]
Termination date of the lease		Jun. 18, 2020
Non-cash lease expense		$ 210,730
Early lease termination fee		150,000
Payments for base rent subject to early termination		$ 900,000
Argus II Product [Member]
Product Information [Line Items]
Impairment charge			500,000	$ 2,400,000
Other assets impairment charge			700,000
Argus II Product [Member] \| Subsequent Event [Member]
Product Information [Line Items]
Impairment charge	$ 700,000
Inventory [Member]
Product Information [Line Items]
Impairment charge			500,000
Finished goods inventory expected to be used for future warranty claims			750,000
Fixed Assets [Member]
Product Information [Line Items]
Impairment charge			$ 400,000

Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details)	3 Months Ended
	Mar. 31, 2019
United States
Concentration Risk [Line Items]
Geographic concentration	60.00%
Italy
Concentration Risk [Line Items]
Geographic concentration	23.00%
Korea
Concentration Risk [Line Items]
Geographic concentration	10.00%

Subsequent Events - Additional Information (Details)	May 27, 2020 USD ($) shares	May 08, 2020 USD ($)	May 05, 2020 USD ($) $ / shares shares	May 13, 2020 USD ($)	Mar. 31, 2020 Employee
Subsequent Event [Line Items]
Number of retained employees \| Employee					10
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued upon right offering \| shares			7,500,000
Share price (in dollars per share) \| $ / shares			$ 1.00
Proceeds from issuance or sale of equity, total			$ 6,600,000
Gross proceeds from issuance or sale of shares			$ 7,500,000
Subsequent Event [Member] \| Employee Stock Purchase Plan [Member]
Subsequent Event [Line Items]
Repurchase and cancelation of common stock, Shares \| shares	39,467
Repurchase and cancelation of common stock, Value	$ 270,000
Chief Financial Officer [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
One time bonus				$ 100,000
Chief Operating Officer [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Termination payment		$ 471,000
Maximum period for reimbursement of COBRA		12 months
Termination date		Apr. 17, 2020

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Allocated share-based compensation expense	$ 279	$ 898
Cost of Sales
Allocated share-based compensation expense		47
Research and Development
Allocated share-based compensation expense	102	187
Clinical and Regulatory
Allocated share-based compensation expense	15	34
Selling and Marketing
Allocated share-based compensation expense	41	130
General and Administrative
Allocated share-based compensation expense	$ 121	$ 500

Warrants - Summary of Warrants Activity (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding at beginning	7,682,000
Outstanding at ending	7,682,000	7,682,000
Exercisable at ending	7,682,000
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at beginning	$ 11.76
Outstanding at ending	11.76	$ 11.76
Exercisable at ending	$ 11.76
Class of Warrant or Right, Weighted Average Remaining Contractual Life of Warrants or Rights [Roll Forward]
Outstanding at ending	3 years 11 months 15 days	4 years 2 months 15 days
Exercisable at ending	3 years 11 months 15 days

Selected Balance Sheet Detail - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Lease expense:
Operating lease expense	$ 123	$ 123
Total lease expense	$ 123	$ 123

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (8,886)	$ (9,700)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	106	99
Stock-based compensation	279	898
Non-cash lease expense	3	6
Restructuring charges-inventory and fixed asset impairment	1,115	2,424
Changes in operating assets and liabilities:
Accounts receivable	455	(95)
Inventories	(112)	(786)
Prepaid expenses and other assets	(610)	236
Accounts payable	497	297
Accrued expenses	286	(57)
Accrued compensation expenses	(1,813)	(609)
Accrued clinical trial expenses	26	84
Contract liabilities		53
Net cash used in operating activities	(8,654)	(7,150)
Cash flows from investing activities:
Purchases of property and equipment	(331)	(37)
Net cash used in investing activities	(331)	(37)
Cash flows from financing activities:
Net proceeds from sale of common stock and/or warrants	6	34,399
Repurchase of fractional shares in connection with reverse stock split	(11)
Net cash (used in) provided by financing activities	(5)	34,399
Effect of exchange rate changes on cash and cash equivalents	2	(1)
Cash and cash equivalents:
Net increase (decrease)	(8,988)	27,211
Balance at beginning of period	11,327	4,471
Balance at end of period	$ 2,339	$ 31,682

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	15,657,000	15,643,000
Common stock, shares outstanding (in shares)	15,657,000	15,643,000

Concentration of Risk - Schedule of Concentration of Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2019
Customer 1 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	23.00%
Customer 1 [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration		35.00%
Customer 2 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	15.00%
Customer 2 [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration		33.00%
Customer 3 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	13.00%
Customer 3 [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration		32.00%
Customer 4 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	12.00%
Customer 5 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	12.00%
Customer 6 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%
Customer 7 [Member] \| Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%

Equity Securities - Additional Information (Details) - $ / shares	Mar. 31, 2020	Dec. 31, 2019	Jun. 04, 2019	Mar. 31, 2019
Equity [Abstract]
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000	200,000,000

Risk and Uncertainties - Additional Information (Details)	Mar. 31, 2020 Employee
Risks And Uncertainties [Abstract]
Number of retained employees	10

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance beginning at Dec. 31, 2018	$ 3,084	$ 229,019	$ (575)	$ 44,111	$ (269,471)
Balance beginning (in shares) at Dec. 31, 2018		9,542,000
Adoption of ASC Topic 842-Leases (see note 2) at Dec. 31, 2018	(144)				(144)
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs	34,399	$ 34,399
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares)		5,976,000
Release of restricted stock units (shares)		7,000
Warrants modification (see note 7)				1,577	(1,577)
Stock-based compensation expense	898			898
Net loss	(9,700)				(9,700)
Foreign currency translation adjustment	(8)		(8)
Balance ending at Mar. 31, 2019	28,529	$ 263,418	(583)	46,586	(280,892)
Balance ending (in shares) at Mar. 31, 2019		15,525,000
Balance beginning at Dec. 31, 2019	$ 7,275	$ 264,008	(562)	48,613	(304,784)
Balance beginning (in shares) at Dec. 31, 2019	15,643,000	15,643,000
Repurchase of fractional shares in connection with reverse stock split	$ (11)	$ (11)
Repurchase of Fractional Shares In Connection With Reverse Stock Split (In Shares)		(2,000)
Issuance of shares of common stock	6	$ 6
Issuance of shares of common stock, Shares		1,000
Release of restricted stock units (shares)		15,000
Stock-based compensation expense	279			279
Net loss	(8,886)				(8,886)
Foreign currency translation adjustment	19		19
Balance ending at Mar. 31, 2020	$ (1,318)	$ 264,003	$ (543)	$ 48,892	$ (313,670)
Balance ending (in shares) at Mar. 31, 2020	15,657,000	15,657,000

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,339	$ 11,327
Accounts receivable, net		455
Inventories, net		1,029
Assets held-for-sale	400
Prepaid expenses and other current assets	926	299
Total current assets	3,665	13,110
Property and equipment, net	232	1,122
Right-of-use assets		2,342
Deposits and other assets	7	25
Total assets	3,904	16,599
Current liabilities:
Accounts payable	1,588	1,093
Accrued expenses	1,575	1,889
Accrued compensation expense	885	2,698
Accrued clinical trial expenses	733	707
Current operating lease liabilities	106	237
Contract liabilities	335	335
Total current liabilities	5,222	6,959
Long term operating lease liabilities		2,365
Total liabilities	5,222	9,324
Commitments and contingencies
Stockholders’ equity (deficiency):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,657 and 15,643 as of March 31, 2020 and December 31, 2019, respectively	264,003	264,008
Additional paid-in capital	48,892	48,613
Accumulated other comprehensive loss	(543)	(562)
Accumulated deficit	(313,670)	(304,784)
Total stockholders’ equity (deficiency)	(1,318)	7,275
Total liabilities and stockholders’ equity (deficiency)	$ 3,904	$ 16,599

Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 653	$ 4,778
Accumulated depreciation and amortization	(421)	(3,656)
Property and equipment, net	232	1,122
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	584	2,724
Computer Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 69	1,672
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		304
Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		$ 78

Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Right-of-use assets		$ 2,342
Liabilities
Current operating lease liabilities	$ 106	237
Long term operating lease liabilities		$ 2,365

Litigation, Claims and Assessments - Additional Information (Details)	Jun. 23, 2020 USD ($)
Disclosure Text Block [Abstract]
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 3,000,000